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In an effort to improve biological activities and to examine antimycobacterial-lipophilicity relationships
of 2-[(1E)-alkenyl)]-4-(1H)-quinolones, we have synthesized a series of 30 quinolones by introducing
several alkyl groups, an alkenyl and an alkynyl group at N-1. All synthetic compounds were ﬁrst tested in
vitro against Mycobacterium smegmatis and the most active compounds (MIC valuesw3.0e7.0 mM) were
further examined against three other rapidly growing strains of mycobacteria using a microtiter broth
dilution assay. The Clog P values of the synthetic compounds were calculated to provide an estimate of
their lipophilicity. Compounds 18e, 19a and 19b displayed the most potent inhibitory effect against
M. smegmatis mc2155 with an MIC value of w1.5 mM, which was twenty fold and thirteen fold more
potent than isoniazid and ethambutol, respectively. On the other hand, compounds 17e, 18e and 19a
were most active against Mycobacterium fortuitum and Mycobacterium phlei with an MIC value of
w3.0 mM. In the human diploid embryonic lung cell line MRC-5 cytotoxicity assay, the derivatives
showed moderate to strong cytotoxic activity. Although the antimycobacterial activity of our synthetic
compounds could not be correlated with the calculated log P values, an increase in lipophilicity enhances
the antimycobacterial activity and C13eC15 total chain length at positions 1 and 2 is required to achieve
optimal inhibitory effect against the test strains.
 2011 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Since the discovery of nalidixic acid in the early 1960s, quino-
lones have been the subject of continuous academic interest and
various structural modiﬁcations have resulted in second, third and
fourth-generation quinolone antibiotics, which are currently in the
market. Continuous modiﬁcations in the basic structure of quino-
lones have increased their antibacterial spectrum and potency,
making quinolones useful for the treatment of urinary, systemic
and respiratory tract infections. Furthermore, along with other
antibacterial agents, quinolones have been used extensively in
veterinary practice, either as antibacterial or as growth promoters.
Various studies blame their wide spread overuses and misuses for
emergency of resistance to quinolones [1]. Ciproﬂoxacin, for
example, is the most consumed antibacterial quinolone worldwide
[2], and consequentlymost exposed to resistance. In the last decade
there is a dramatic increase in the number of quinolone: þ43 3163809846.
ner).
nder CC BY-NC-ND license.antimycobacterial agents under development, which is mainly
driven by the problem of multi-drug resistance. Multi drug resis-
tant tuberculosis (MDR-TB) is treated with second-line drugs,
where treatment takes two years or longer and is expensive. Some
of the ﬂuoroquinolones used to treat MDR-TB are too toxic as they
were not originally developed speciﬁcally for tuberculosis. The
emergency of extensively drug resistant tuberculosis (XDR-TB)
further complicated the treatment and management of TB. There-
fore, new drugs with newmode of action are required to cope with
this disturbing trend of drug resistance.
Although a series of ﬂuoroquinolone derivatives containing
a carboxyl group at C-3 have been synthesized and are commer-
cially available for the treatment of many types of infectious
diseases including tuberculosis, no attempt has been made to
evaluate the antimycobacterial potential of quinolones with an
aliphatic substituent at position 2. In our previous studies we dis-
closed the antimycobacterial properties of 1-methyl-2-alkenyl-4-
(1H)-quinolones isolated from the fruits of Euodia rutaecarpa Hook
f. & Thomson (Rutaceae) [3,4]. Very recently, we have reported the
structural requirements for potent antimycobacterial activities of
1-methyl-2-alkenyl-4-(1H)-quinolones derivatives [5]. Results of
A.A. Wube et al. / European Journal of Medicinal Chemistry 46 (2011) 2091e21012092our studies revealed that lipophilicity is essential for growth inhi-
bition and compounds having C11eC14 alkenyl groups at C-2 dis-
played potent inhibitory effects compared to the antibiotics
ethambutol and isoniazid. In an effort to improve the anti-
mycobacterial activities and further explore the structure-activity
relationships at position 1, in this paper, we report synthesis and
antimycobacterial activity evaluation of 2-alkenyl-4-(1H)-quino-
lones possessing ethyl, propyl, butyl or pentyl group at N-1. To
further assess whether unsaturated groups at N-1 has any impact
on the activity of compounds of this type, 2-propenyl and 2-pro-
pynyl groups were introduced to position 1.2. Results and discussion
2.1. Chemistry
In order to identify more potent antimycobacterial agents and to
examine the lipophilicity-antimycobacterial relationship, thirty
derivatives were synthesized and evaluated. The synthesis route to
N-substituted 2-[(1E)-alkenyl]-4-(1H)-quinolones 16ae21e is dep-
icted in Scheme 1, and the structures of the derivatives are shown in
Table 1. Methylcarbonylmethylenephosphorane (2) required for
Wittig condensation was prepared in high yield according to
previouslydescribedmethods [6]. Subsequent treatmentof theylide
2 with the corresponding aldehydes afforded a,ß-unsaturated
methyl ketones (4e9) with trans conﬁguration in moderate yields.
Isatoic acid anhydride (3) was converted to the corresponding
N-substituted isatoic acid anhydrides 10e15 by the reaction with
alkyl halides in the presence of NaH [7]. Finally, the desired
substances (16ae21e) were obtained by the reaction between
unsaturated methyl ketones (4e9) and N-substituted isatoic anhy-












4: n = 6 (77%)
5: n = 7 (73%)
6: n = 8 (71%)
7: n = 9 (66%)
8: n = 10 (67%)
9: n = 11 (81%)
CH3-(CH2)n
16 a-e: n = 6
17 a-f: n = 7
18 a-f: n = 8 
19 a-f: n = 9
20 a,c,f: n = 10
21 b-e: n = 11
5
8
Scheme 1. Reagents and conditions: i) PPh3, MeCN, reﬂux, 24 h; ii) 1 N NaOH (modiﬁcation. The identity of the quinolones and their correspond-
ing intermediates was conﬁrmed by analysis of 1- and 2D NMR
spectroscopy and LC-ESI-MS data.2.2. In vitro antimycobacterial and cytotoxic activities
All synthetic derivatives were ﬁrst tested againstMycobacterium
smegmatis in our mycobacterial susceptibility assay and the most
active compounds which gave MIC values of 1 and 2 mg/L, were
further evaluated against Mycobacterium fortuitum, Mycobacterium
phlei and M. smegmatis mc2155 (Table 1). Against M. smegmatis
compounds 16e,17e,18b,18c,18e,19aec and 20a (Clog P¼ 6.4e7.4),
bearing N-alkyl groups, displayed the most potent inhibitory effect
with an MIC value of 1 mg/L that was twofold and fourfold more
potent than ethambutol and isoniazid, respectively, but eightfold
less potent than ciproﬂoxacin. In contrast, among N-alkyl bearing
derivatives, compounds 20f and 21e (Clog P value of 9.0)were found
to be least active with MIC value of 128 mg/L. AgainstM. smegmatis
mc2155, which is often used as a model organism to study efﬂux
pump-mediated multi-drug resistance in mycobacteria [9],
compounds 18e,19a and 19b (Clog P values of 6.9 and 7.4) exhibited
the most potent growth inhibition with an MIC value of 0.5 mg/L,
being eightfold more potent than isoniazid and ethambutol. The
other tested substances also displayed signiﬁcant inhibitory effects
with MIC values of 1e2 mg/L. On the other hand, compounds 17e,
18e and 19aweremost active againstM. fortuitum andM. phleiwith
an MIC value of 1 mg/L. Interestingly, compounds 17e and 17b
possessing a 1-decenyl moiety, but having N-butyl and N-propyl,
respectively, showed similar inhibitory effects against all strains,
with MIC values of 1 and 2 mg/L, respectively.
Among compounds 18aef (Clog P ¼ 6.4e7.9) and 19aef (Clog



















10: R = ethyl (82%)
11: R = n-propyl (84%)
12: R = prop-2-en-1-yl (77%)
13: R = prop-2-yn-1-yl (87%)
14: R = n-butyl (80%)
15: R = n-pentyl (70%)
a: R = ethyl 
b: R = n-propyl
c: R = prop-2-en-1-yl
d: R = prop-2-yn-1-yl
e: R = n-butyl










pH ¼ 7e8), iii) THF, reﬂux, 48 h; iv) NaH, DMF, 24 h; v) LDA, THF, 78 C.
Table 1





Compound R R0 Clog P MIC (mM) MIC (mg/mL) Metabolic active cells (%)b
A A B C D 100 mM 30 mM
16a ethyl n-heptyl 5.3 26.9 8 ND ND ND 52.61  8.51 96.64  1.28
16b n-propyl n-heptyl 5.8 12.9 4 ND ND ND 7.40  5.52 32.94  7.07
16c 2-propenyl n-heptyl 5.5 25.9 8 ND ND ND 0.53  0.04 10.05  0.15
16d 2-propynyl n-heptyl 4.9 6.5 2 2 32 4 63.86  2.82 71.08  1.40
16e n-butyl n-heptyl 6.4 3.1 1 2 2 2 0.04  0.05 42.92  3.73
17a ethyl n-octyl 5.8 12.9 4 ND ND ND 0.53  0.06 39.16  8.49
17b n-propyl n-octyl 6.4 6.2 2 2 2 2 0.50  0.06 56.09  4.18
17c 2-propenyl n-octyl 6.1 6.2 2 1 4 2 0.63  0.05 32.96  8.00
17d 2-propynyl n-octyl 5.4 49.8 16 ND ND ND 0.40  0.05 43.57  9.94
17e n-butyl n-octyl 6.9 2.9 1 1 1 1 0.55  0.05 55.14  3.69
17f n-pentyl n-octyl 7.4 5.7 2 1 4 4 0.46  0.05 61.71  3.84
18a ethyl n-nonyl 6.4 6.2 2 1 2 2 0.50  0.08 91.31  1.86
18b n-propyl n-nonyl 6.9 2.9 1 1 4 2 0.71  0.07 3.64  2.02
18c 2-propenyl n-nonyl 6.6 3.0 1 2 2 2 0.19  0.23 75.05  0.86
18d 2-propynyl n-nonyl 5.9 11.9 4 ND ND ND 26.34  6.30 92.31  1.26
18e n-butyl n-nonyl 7.4 2.8 1 0.5 1 1 0.44  0.07 15.11  6.13
18f n-pentyl n-nonyl 7.9 10.9 4 ND ND ND 0.38  0.04 41.60  5.69
19a ethyl n-decyl 6.9 2.9 1 0.5 1 1 0.69  0.04 97.86  2.43
19b n-propyl n-decyl 7.4 2.8 1 0.5 2 2 0.65  0.03 4.20  1.87
19c 2-propenyl n-decyl 7.1 2.8 1 1 2 2 1.06  0.08 19.75  5.91
19d 2-propynyl n-decyl 6.5 183.4 64 ND ND ND 0.64  0.15 40.71  7.08
19e n-butyl n-decyl 7.9 10.9 4 ND ND ND 0.45  0.07 42.40  8.98
19f n-pentyl n-decyl 8.5 21.0 8 ND ND ND 0.25  0.06 31.6  0.32
20a ethyl n-undecyl 7.4 2.8 1 1 4 2 0.60  0.05 100.00  2.16
20c 2-propenyl n-undecyl 7.7 10.9 4 ND ND ND 1.06  0.03 17.92  4.46
20f n-pentyl n-undecyl 9.0 324.1 128 ND ND ND 0.25  0.04 11.74  0.06
21b n-propyl n-dodecyl 8.5 42.0 16 ND ND ND 0.72  0.16 42.60  6.02
21c 2-propenyl n-dodecyl 8.2 42.2 16 ND ND ND 0.70  0.07 98.16  1.42
21d 2-propynyl n-dodecyl 7.5 339.5 128 ND ND ND 10.00  5.51 100.21  1.53
21e n-butyl n-dodecyl 9.0 324.1 128 ND ND ND 0.51  0.18 10.93  7.10
Isoniazid ND 29.2 4 4 1 16 ND ND
Ethambutol ND 9.8 2 4 16 4 ND ND
Ciproﬂoxacin ND 0.4 0.125 ND ND ND ND ND
Vinblastin at 0.12 mM ND ND ND ND ND ND 60.06  4.11
A isM. smegmatis (ATCC 14468); B isM. smegmatismc2155; C isM. fortuitum (ATCC 6841); D isM. phlei (ATCC 11758); Clog P values were determined using ChemDraw Ultra
Version 6.1.
a ND- not determined.
b Cytotoxicity against human diploid embryonic lung cell line MRC-5 compared to control cells (treated with 0.1% EtOH), 72 h incubation time, mean  SEM, n ¼ 6.
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in lipophilicity at position 1. However, among compounds 16ae16e
(Clog P ¼ 5.3e6.4), containing 1-nonenyl moiety, the activity
increases with increase in lipophilicity at N-1. Among compounds
20ae20f and 21be21e a dramatic loss in activitywas observedwith
further increase in lipophilicity. Among theN-ethyl derivatives,16a,
17a, 18a, and 19a, interesting structural-activity relationship is
observed. Starting from 16a to 19a each additionalmethylene group
in the aliphatic side chain at position 2 causes a twofold enhance-
ment of the antimycobacterial activity againstM. smegmatis.
Compared to the other strains M. fortuitumwas found to be less
susceptible towards this group of synthetic quinolones. Among the
compounds tested againstM. fortuitum andM. phlei, compound 17e
bearing butyl and 1-decenyl groups, compound 18e bearing butyl
and undecenyl groups and compound 19a having an ethyl and
a dodecenyl group at N-1 and C-2 positions, respectively, showed
the highest activity with MIC value of 1 mg/L.
The antimycobacterial activities of compounds 16e, 17e and 18e,
all bearing an N-butyl residue but differing in the length of thealiphatic chain at C-2, against M. smegmatis are similar, suggesting
that the increase in lipophilicity appear to have no effect upon anti-
mycobacterial activity. However, among compounds 17f,18f and 19f,
all bearing N-pentyl but containing decenyl, undecenyl and dode-
cenyl group, respectively, a twofolddecrease inactivitywas observed
for chain elongation by a methylene group at C-2. Elongation of the
alkenyl chain to 14 carbonswith introduction of various alkyl groups
at N-1 led to compounds with lower activity. These results reinforce
our previous observations that a certain level of lipophilicity is the
basic requirement for our quinolones activity against the less path-
ogenic mycobacterial strains employed in our study.
Several reports also discussed the structure-activity relationship
between alkyl substituent at N-1 and the antimycobacterial activ-
ities of ﬂuoroquinolones [10e13].
In order to understand the inﬂuence of further structural
requirements at position 1 of the quinolones for antimycobacterial
activity, we have introduced various alkyls, an alkenyl and an
akynyl group at position 1. Various studies have revealed that the
presence of a hydrophobic substituent at N-1 of quinolones has an
A.A. Wube et al. / European Journal of Medicinal Chemistry 46 (2011) 2091e21012094effect on pharmacokinetics and is essential to control antibacterial
potency [14]. Introduction of a t-butyl group was also reported to
enhance antibacterial potency of ﬂuoroquinolones [15,16].
To compare the antimycobacterial activity with toxicity to
mammaliancells, the cytotoxic activityof the synthesizedquinolones
was evaluated using the human diploid embryonic lung cell line
MRC-5, which can be used for further antimycobacterial investiga-
tions like both antimycobacterial and host-cell toxicity studies [17].
Percentage of metabolic viable cells at 30 and 100 mM as given in
Table 1 indicated the degree of the cytotoxicity of our compounds.
At 100 mM most of our compounds showed high cytotoxic
activity, but among the compounds with the highest activity
against M. smegmatis (ATCC 14468), of which the IC50 values were
determined (see Table 2), 17e and 18a showed selectivity to the
mycobacterial cells as indicated by selectivity index (SI) values of 13
and 14, respectively. In addition, compounds 18c, 19a and 20a
displayed low cytotoxicity and good antimycobacterial selectivity
with SI values ranging from 19 to 27. In contrast to the anti-
mycobacterial-lipophilicity relationship, where mycobacterial
growth inhibition decreases with increase in Clog P values, the
most lipophilic compounds 20f and 21e were found to be toxic to
the human diploid embryonic lung cell line MRC-5.
In our recent investigation, we have disclosed the importance of
the double bond in the aliphatic side chain at C-2 for mycobacterial
growth inhibition [5]. To further assess the effect of unsaturated
lipophilic groups on the antimycobacterial activities, we introduced
2-propenyl and 2-propynyl groups at position 1. Comparing the
activities of the compounds 16c and 16d, 17c and 17d, 18c and 18d,
19c and 19d, 21c and 21d bearing N-2-propenyl and N-2-propynyl
groups the increase in degree of unsaturation seems to be of less
important than the lipophilic property, since except compound 16d
(Clog P ¼ 4.9; MIC ¼ 2 mg/L), the N-2-propynyl derivatives were
found to be 4e64 fold less active than the corresponding N-2-
propenyl derivatives. It is therefore reasonable to suggest that the
triple bond in the 2-propynyl group, which results in lower Clog P
values compared to themore saturated analogues, is less signiﬁcant
for mycobacterial growth inhibition than the double bond in the
2-propenyl moiety.
3. Conclusion
To improve antimycobacterial potency and explore the struc-
ture-activity relationships, we synthesized a series of 30 new
N-substituted-2-[(1E)-alkenyl]-4-(1H)-quinolones having different
lipophilic groups at position 1 and 2. Compounds bearing C13eC15
aliphatic groups in the entire molecule, position 1 and 2, appeared
to exert the highest potency against all four mycobacterial test
strains. The results of this study are consistent with our previousTable 2
Selectivity index againstM. smegmatis (ATCC 14468) for the most antimycobacterial
compounds.
Compound MIC (mM) IC50 (mM) SI
16e 3.1 26  3.5 8.4
17e 2.9 36.6  3.6 12.6
18a 6.1 82.7  2.3 13.6
18b 2.9 12.7  2.5 4.4
18c 3.0 57.1  1.0 19.0
18e 2.8 6.3  2.5 2.3
19a 2.9 79.3  2.6 27.3
19b 2.8 13  2.4 4.6
19c 2.8 17.3  2.2 6.2
20a 2.8 52.9  2.6 18.9
IC50 values of MRC-5 cells were determined in three concentrations, each in at least
six independent experiments using SigmaPlot program package employing the 4-
parameter logistic regression model. Results are given as mean  SEM. SI calculated
as IC50/MIC.ﬁndings that 1-methyl-2-alkenyl-4-(1H)-quinolones with C12eC15
unsaturated aliphatic groups at position 2 are endowed with
a potent antimycobacterial activity. The various substituents at




Strains of M. smegmatis (ATCC 14468), M. smegmatis mc2 155,
M. fortuitum (ATCC 6841) andM. phlei (ATCC 11758) were obtained
from American Type Culture Collection or German Collection of
Microorganisms and Cell Culture (DSMZ).
All chemicals were purchased from SigmaeAldrich, Germany.
THF was distilled from sodium. DMF was distilled from CaH2.
Melting points were determined with KOFLER microscope and are
uncorrected. IR spectra obtained on a PerkineElmer 281 B spec-
trometer, were recorded in KBr. 1H and 13C NMR spectra were
recorded on a Varian 400 MHz spectrometer (400 and 100 MHz,
respectively) using deuterated chloroform as solvent with TMS as
internal standard. Mass spectra were obtained by LC-ESI-MS anal-
ysis on positive mode on a Thermo Finnigan LCQ Deca XP Plus mass
spectrometer connected to a Surveyor LC-system (Thermo-Fin-
nigan). Precoated Si gel 60 F254 plates (Merck, Darmstadt) were
used to monitor the progress of the reactions and column fractions.
Spots were detected by UV/254 nm and spraying with molybdo-
phosphoric acid and subsequent heating. Compoundswere puriﬁed
by column chromatography on silica gel 60 (0.063e0.200 mm)
using cyclohexane/ethyl acetate mixtures as eluent.
4.2. Chemistry
4.2.1. Synthesis of a,ß-unsaturated ketones (4e9)
The synthesis was conducted analogous to previously reported
procedures [5] from methylcarbonylmethylenephosphorane (2)
(1 equiv.) and the corresponding aldehyde (0.75 equiv.) in THF.
4.2.1.1. (E)-3-Undecen-2-one (4). Prepared from methylcarbony-
lmethylenephosphorane (2) (15.0 g, 47.2 mmol) and octanal (4.5 g,
35.4 mmol) in THF (350 mL) as a colourless oil (6.1 g, 77%); and its
spectral data agree with the literature [18].
4.2.1.2. (E)-3-Dodecen-2-one (5). Prepared from methylcarbonyl-
methylenephosphorane (2) (15.0 g, 47.2 mmol) and nonanal (5.0 g.
35.4mmol) inTHF (350mL). 5was obtained as a colourless oil (6.3 g,
73%).1HNMR: d6.78 (dt, J¼16.1, 6.7Hz,1H,H-4), 6.05 (bd J¼16.1Hz,
1H, H-3), 2.21 (s, 3H, H-1), 2.19 (m, 2H, H-5), 1.44 (m, 2H, H-6),
1.23e1.32 (m, 10H, H-7e11), 0.86 (t, J ¼ 6.7 Hz, 3H, H-12). 13C NMR:
d 198.6 (C-2), 148.5 (C-4), 131.2 (C-3), 32.4 (C-5), 31.8 (C-10), 29.3,
29.1, 29.1, 28.0, 26.8 (C-1), 22.6 (C-11), 14.0 (C-12).
4.2.1.3. (E)-3-Tridecen-2-one (6). Prepared from methylcarbony-
lmethylenephosphorane (2) (20.0 g, 62.9 mmol) and decanal (7.4 g,
47.2 mmol) in THF (400 mL) as colourless oil (8.8 g, 71%); and its
spectral properties are recently reported [5].
4.2.1.4. (E)-3-Tetradecen-2-one (7). Prepared from methylcarbonyl-
methylenephosphorane (2) (20.0 g, 62.9mmol) and undecanal (8.0 g,
47.2 mmol) in THF (400 mL). 7 was formed as a colourless oil (8.7 g,
66%). 1H NMR: d 6.75 (dt, J¼ 16.1, 6.6 Hz,1H, H-4), 6.02 (d, J¼ 16.1 Hz,
1H, H-3), 2.18 (s, 3H, H-1), 2.15 (m, 2H, H-5), 1.43 (m, 2H, H-6),
1.22e1.31 (m, 14H, H-7e13), 0.84 (t, J ¼ 6.6 Hz, 3H, H-14). 13C NMR:
d198.6 (C-2),148.5 (C-4),131.2 (C-3), 32.5 (C-5), 31.8 (C-12), 29.4, 29.3,
29.2, 29.1, 29.1, 28.0, 26.7 (C-1), 22.6 (C-13), 14.0 (C-14).
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onylmethylenephosphorane (2) (20.0 g, 62.9 mmol) and dodecanal
(8.7 g, 47.2 mmol) in THF (400 mL). 8 was obtained as a colourless
oil (9.4 g, 67%). 1H NMR: d 6.78 (dt, J ¼ 16.1, 6.7 Hz, 1H, H-4), 6.05
(bd, J ¼ 16.1 Hz, 1H, H-3), 2.20 (s, 3H, H-1), 2.17 (m, 2H, H-5), 1.44
(m, 2H, H-6), 1.21e1.33 (m, 16H, H-7e14), 0.86 (t, J ¼ 6.7 Hz, 3H,
H-15). 13C NMR: d 198.4 (C-2), 148.3 (C-4), 131.2 (C-3), 32.4 (C-5),
31.8 (C-13), 29.5, 29.4, 29.3, 29.2, 29.1, 29.1, 28.0, 26.8 (C-1), 22.6
(C-14), 14.0 (C-15).
4.2.1.6. (E)-3-Hexadecen-2-one (9). Prepared from methyl-
carbonylmethylenephosphorane (2) (15.0 g, 47.2 mmol) and tri-
decanal (8.4 g, 35.4 mmol) in THF (350 mL). 9 was obtained as
a colourless oil (9.1 g, 81%). 1H NMR: d 6.77 (dt, J ¼ 16.1, 6.7 Hz, 1H,
H-4), 6.03 (bd, J ¼ 16.1 Hz, 1H, H-3), 2.19 (s, 3H, H-1), 2.16 (m, 2H,
H-5), 1.44 (m, 2H, H-6), 1.21e1.33 (m, 18H, H-7e15), 0.85 (t,
J¼ 6.7 Hz, 3H, H-16). 13C NMR: d 198.5 (C-2),148.4 (C-4), 131.2 (C-3),
32.6 (C-5), 31.8 (C-14), 29.4, 29.5, 29.4, 29.3, 29.2, 29.1, 29.1, 28.0,
26.8 (C-1), 22.6 (C-15), 14.0 (C-16).
4.2.2. General procedure for the synthesis of N-substituted isatoic
acid anhydrides (10e15)
Sodium hydride (60% dispersion in mineral oil) was washed
with hexane and 1.0 equiv of the dry NaH was added slowly in
portions to a stirring solution of isatoic acid anhydride (1.0 equiv) in
absolute DMF. After 1 h of stirring alkyl halide (1.5 equiv) was
added and stirring continued for 24 h. DMF was removed under
reduced pressure and the residue was poured into ice water and
extracted with ether. The crude product was puriﬁed by column
chromatography eluting with cyclohexane/ethyl acetate (9:1) to
afford the corresponding N-substituted isatoic acid anhydride.
4.2.2.1. N-Ethyl-isatoic acid anhydride (10). Starting from isatoic
acid anhydride (3) (16.3 g, 0.1 mol) in DMF (150 mL), NaH 60%
dispersion in mineral oil (4.1 g, 0.1 mol) and ethyl iodide (23.4 g,
0.15 mol). 10 was obtained as light yellow solid (15.6 g, 82%), m.p.
115e117 C. 1H NMR: d 8.18 (d, J¼ 8.0 Hz,1H, H-5), 7.77 (t, J¼ 8.0 Hz,
1H, H-7), 7.28 (t, J ¼ 8.0 Hz, 1H, H-6), 7.19 (d, J ¼ 8.4 Hz, 1H, H-8),
4.14 (q, J ¼ 7.2 Hz, 2H, NeCH2eCH3), 1.49 (t, J ¼ 6.8 Hz, 3H,
NeCH2eCH3). 13C NMR: d 158.6 (C-4), 147.7 (C-2), 141.2 (C-8a), 137.3
(C-7), 130.8 (C-5), 123.7 (C-6), 114.6 (C-8), 111.5 (C-4a), 40.3
(NeCH2eCH3), 14.1 (NeCH2eCH3).
4.2.2.2. N-Propyl isatoic acid anhydride (11). Starting from isatoic
acid anhydride (3) (16.3 g, 0.1 mol) in DMF (150 mL), NaH 60%
dispersion in mineral oil (4.1 g, 0.1 mol) and 1-iodopropane
(25.5 g, 0.15 mol).11was obtained as light yellow solid (17.2 g, 84%),
m.p. 93e95 C. 1H NMR: d 8.09 (dd, J¼ 8.0, 1.6 Hz, 1H, H-5), 7.75 (td,
J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.26 (t, J ¼ 8.0 Hz, 1H, H-6), 7.17
(d, J ¼ 8.4 Hz, 1H, H-8), 4.00 (t, J ¼ 8.0 Hz, 2H, NeCH2eCH2eCH3),
1.76 (sext, J ¼ 7.6 Hz, 2H, NeCH2eCH2eCH3), 1.01 (t, J ¼ 6.8 Hz, 3H,
Ne(CH2)2eCH3). 13C NMR: d 158.5 (C-4), 147.6 (C-2), 141.2 (C-8a),
137.2 (C-7), 130.7 (C-5), 123.8 (C-6), 113.9 (C-8), 111.5 (C-4a),
46.3 (NeCH2eCH2eCH3), 20.1 (NeCH2eCH2eCH3), 10.9 (Ne(CH2)2
eCH3).
4.2.2.3. N-2-Propenyl isatoic acid anhydride (12). Starting from
isatoic acid anhydride (3) (8.3 g, 0.05mol) in DMF (90mL), NaH 60%
dispersion in mineral oil (2.1 g, 0.05 mol) and allyl bromide (9.1 g,
0.075 mol). 12 was obtained as yellowish solid (7.8 g, 77%), m.p.
104e106 C. 1H NMR: d 8.09 (d, J ¼ 8.0 Hz, 1H, H-5), 7.73 (t,
J ¼ 8.0 Hz, 1H, H-7), 7.27 (t, J ¼ 7.6 Hz, 1H, H-6), 7.16 (d, J ¼ 8.4 Hz,
1H, H-8), 5.91 (ddt, J¼ 17.2,10.0, 4.0 Hz,1H,NeCH2eCH]CH2), 5.30
(d, J ¼ 10.0 Hz, 1H, NeCH2eCH]CHHb), 5.26 (d, J ¼ 17.2 Hz, 1H,
NeCH2eCH]CHaH), 4.68 (d, J ¼ 1.6 Hz, 2H, NeCH2eCH]CH2). 13CNMR: d 158.3 (C-4), 147.6 (C-2), 141.2 (C-8a), 137.2 (C-7), 130.5 (C-5),
129.9 (NeCH2eCH]CH2), 123.9 (C6), 118.4 (NeCH2eCH]CH2),
114.5 (C-8), 111.4 (C-4a), 46.9 (NeCH2eCH]CH2).
4.2.2.4. N-2-Propynyl isatoic acid anhydride (13). Prepared from
isatoic acid anhydride (3) (8.3 g, 0.05 mol) in DMF (90mL), NaH 60%
dispersion in mineral oil (2.1 g, 0.05 mol) and propargyl bromide
(8.9 g, 0.075 mol). 13 was obtained as yellowish solid (8.7 g, 87%
yield), m.p. 131e133 C. 1H NMR: d 8.14 (d, J ¼ 8.0 Hz, 1H, H-5), 7.81
(t, J¼ 8.0 Hz, 1H, H-7), 7.36 (d, J¼ 7.6 Hz,1H, H-8), 7.34 (t, J¼ 7.6 Hz,
1H, H-6), 4.86 (s, 2H, NeCH2eChCH), 2.37 (s, 1H, NeCH2eChCH).
13C NMR: d 157.9 (C-4), 147.9 (C-2), 140.3 (C-8a), 137.3 (C-7), 130.8
(C-5), 124.4 (C-6), 114.4 (C-8), 111.7 (C-4a), 75.9 (NeCH2eChCH),
74.3 (NeCH2eChCH), 34.5 (NeCH2eChCH).
4.2.2.5. N-Butyl isatoic acid anhydride (14). Prepared from isatoic
acid anhydride (3) (8.3 g, 0.05 mol) in DMF (90 mL), NaH 60%
dispersion in mineral oil (2.1 g, 0.05 mol) and 1-iodobutane (13.8 g,
0.075 mol). 14 was obtained as yellowish solid (8.8 g, 80%), m.p.
58e60 C. 1H NMR: d 8.07 (d, J ¼ 8.0 Hz, 1H, H-5), 7.75 (t, J ¼ 8.0 Hz,
1H, H-7), 7.24 (t, J¼ 8.0 Hz,1H, H-6), 7.17 (d, J¼ 8.4 Hz,1H, H-8), 4.02
(t, J ¼ 7.6 Hz, 2H, NeCH2e(CH2)2eCH3), 1.70 (quint, J ¼ 6.8 Hz, 2H,
NeCH2eCH2eCH2eCH3), 1.42 (m, 2H, Ne(CH2)2eCH2eCH3), 0.95 (t,
J ¼ 6.8 Hz, 3H, Ne(CH2)3eCH3). 13C NMR: d 158.4 (C-4), 147.5 (C-2),
141.1 (C-8a), 137.1 (C-7), 130.5 (C-5), 123.7 (C-6), 113.9 (C-8), 111.5
(C-4a), 44.6 (NeCH2e(CH2)2eCH3), 28.7 (NeCH2eCH2eCH2eCH3),
18.7 (Ne(CH2)2eCH2eCH3), 13.5 (Ne(CH2)3eCH3).
4.2.2.6. N-Pentyl isatoic acid anhydride (15). Prepared from isatoic
acid anhydride (3) (16.3 g, 0.1 mol) in DMF (150 mL), NaH 60%
dispersion in mineral oil (4.1 g, 0.1 mol) and 1-bromopentane
(22.7 g, 0.15 mol). 15 was obtained as yellowish solid (16.4 g, 70%),
m.p. 55e57 C. 1H NMR: d 8.15 (d, J ¼ 8.0 Hz, 1H, H-5), 7.75 (t,
J¼ 8.0 Hz,1H, H-7), 7.28 (t, J¼ 8.0 Hz,1H, H-6), 7.15 (d, J¼ 8.4 Hz,1H,
H-8), 4.04 (t, J ¼ 8.0 Hz, 2H, NeCH2e(CH2)3eCH3), 1.70 (quint,
J ¼ 6.8 Hz, 2H, NeCH2eCH2e(CH2)2eCH3), 1.40 (m, 4H, Ne(-
CH2)2eCH2eCH2eCH3), 0.94 (t, J ¼ 6.8 Hz, 3H, Ne(CH2)4eCH3). 13C
NMR: d 158.5 (C-4), 147.7 (C-2), 141.3 (C-8a), 137.1 (C-7), 130.9 (C-5),
123.8 (C-6), 113.8 (C-8), 111.9 (C-4a), 44.9 (NeCH2e(CH2)3eCH3),
29.3 (Ne(CH2)3eCH2eCH3), 28.9 (NeCH2eCH2e(CH2)2eCH3), 22.4
(Ne(CH2)3eCH2eCH3), 13.9 (Ne(CH2)4eCH3).
4.2.3. Synthesis of N-substituted 2-(1E-alkenyl)-4-(1H)-quinolones
(16ae21e)
These substances were prepared from a,ß-unsaturated ketones
(4e9) and N-substituted isatoic acid anhydrides (10e15) in the
presence of LDA as previously described method [5].
4.2.3.1. 1-Ethyl-2-[(1E)-nonenyl]-4-(1H)-quinolone (16a). Prepared
from (E)-3-undecen-2-one (4) (1.0 g, 5.9 mmol) in THF (20mL), LDA
(3.0 mL, 5.9 mmol) and N-ethyl isatoic acid anhydride (10) (0.85 g,
4.5 mmol) in THF (20 mL). 16a was formed as yellow semisolid
(0.62g, 46%). IR (KBr,nmax, cm1): 3443, 2926, 2854,1624,1597,1486,
1436,1186,1119, 722, 540.1HNMR: d8.38 (dd, J¼8.4,1.6Hz,1H,H-5),
7.59 (td, J ¼ 8.4, 1.6 Hz, 1H, H-7), 7.43 (d, J ¼ 8.0 Hz, 1H, H-8), 7.27
(t, J¼ 7.2 Hz,1H, H-6), 6.38 (d, J¼ 15.6 Hz,1H, H-10), 6.34 (s,1H, H-3),
6.30 (dt, J ¼ 15.6, 6.8 Hz, 1H, H-20), 4.17 (q, J ¼ 6.8 Hz, 2H,
NeCH2eCH3), 2.22 (q, J¼ 7.2 Hz, 2H, H-30),1.45 (quint, J¼ 6.8 Hz, 2H,
H-40),1.38 (t, J¼7.2Hz, 3H,NeCH2eCH3),1.31e1.22 (m, 8H,H-50e80),
0.85 (t, J¼ 6.8 Hz, 3H, H-90). 13C NMR: d 177.5 (C-4),151.6 (C-2),141.8
(C-20),140.1 (C-8a),131.9 (C-7),126.8 (C-4a),126.6 (C-5),123.2 (C-10),
123.0 (C-6), 115.2 (C-8), 109.5 (C-3), 42.3 (NeCH2eCH3), 32.9 (C-30),
31.6(C-70), 28.9 (C-60), 28.9 (C-50), 28.5 (C-40), 22.5 (C-80), 13.9 (C-90),
13.8 (NeCH2eCH3). ESI-MS m/z (%): [M þ 1]þ 298 (100), 268
[M þ 2eC2H5]þ, 254, 226, 212, 198, 172, 159, 120.
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(16b). Prepared from (E)-3-undecen-2-one (4) (1.0 g, 5.9 mmol) in
THF (20 mL), LDA (3.0 mL, 5.9 mmol) and N-propyl isatoic acid
anhydride (11) (0.92 g, 4.5 mmol) in THF (20 mL). 16b was formed
as light yellow oil (0.58 g, 41%). IR (KBr, nmax cm1): 3422, 2926,
2854, 1624, 1598, 1486, 1422, 759, 542. 1H NMR: d 8.41 (dd,
J ¼ 8.4, 1.6 Hz, 1H, H-5), 7.61 (td, J ¼ 8.4, 1.6 Hz, 1H, H-7), 7.44 (d,
J ¼ 8.4 Hz, 1H, H-8), 7.31 (t, J ¼ 7.6 Hz, 1H, H-6), 6.41 (d, J ¼ 15.2 Hz,
1H, H-10), 6.37 (s, 1H, H-3), 6.33 (dt, J ¼ 15.2, 6.8 Hz, 1H, H-20), 4.07
(t, J ¼ 8.0 Hz, 2H, NeCH2eCH2eCH3), 2.25 (q, J ¼ 6.8 Hz, 2H, H-30),
1.81 (m, 2H, NeCH2eCH2eCH3), 1.48 (quint, J ¼ 7.2 Hz, 2H, H-40),
1.33e1.22 (m, 8H, H-50e80), 1.01 (t, J ¼ 7.2 Hz, 3H, Ne(CH2)2eCH3),
0.87 (t, J¼ 6.8 Hz, 3H, H-90). 13C NMR: d 177.5 (C-4),151.9 (C-2),141.9
(C-20), 140.4 (C-8a), 132.0 (C-7), 126.9 (C-4a), 126.7 (C-5), 123.5 (C-
10), 123.1 (C-6), 115.5 (C-8), 109.6 (C-3), 48.9 (NeCH2eCH2eCH3),
33.0 (C-30), 31.7 (C-70), 29.0 (C-60), 29.0 (C-50), 28.5 (C-40), 22.5 (C-
80), 21.9 (NeCH2eCH2eCH3), 13.9 (C-90), 10.9 (Ne(CH2)2eCH3). ESI-
MSm/z (%): [M þ 1]þ 312 (100), 270 [M þ 2eC3H7]þ, 242, 228, 212,
198, 172, 159, 130, 115.
4.2.3.3. 1-(2-Propenyl)-2-[(1E)-nonenyl]-4-(1H)-quinolone (16c). Prepared
from (E)-3-undecen-2-one (4) (1.0 g, 5.9 mmol) in THF (20mL), LDA
(3.0 mL, 5.9 mmol) and N-2-propenyl isatoic acid anhydride (12)
(0.91 g, 4.5 mmol) in THF (20 mL). 16c was formed as yellow oil
(0.68 g, 49%). IR (KBr, nmaxcm1): 3422, 2926, 2854,1623,1598,1486,
1422, 760, 542. 1H NMR: d 8.39 (dd, J¼ 8.0, 1.6 Hz, 1H, H-5), 7.55 (td,
J¼ 8.0,1.6 Hz,1H, H-7), 7.37 (d, J¼ 8.4 Hz,1H, H-8), 7.28 (t, J¼ 7.2 Hz,
1H, H-6), 6.38 (s,1H, H-3), 6.34 (dt, J¼ 16.0, 6.4 Hz,1H, H-20), 6.28 (d,
J ¼ 16.0 Hz, 1H, H-10), 6.00 (ddt, J ¼ 17.2, 10.4, 4.0 Hz, 1H,
NeCH2eCH]CH2), 5.26 (d, J ¼ 10.4 Hz, 1H, NeCH2eCH]CHHb),
4.97 (d, J¼ 17.2 Hz, 1H, NeCH2eCH]CHaH), 4.72 (dt, J¼ 4.0, 1.6 Hz,
2H, NeCH2eCH]CH2), 2.21 (q, J ¼ 6.8 Hz, 2H, H-30), 1.45 (quint,
J¼6.8Hz,2H,H-40),1.34e1.23 (m,8H,H-50e80), 0.85 (t, J¼6.8Hz, 3H,
H-90). 13C NMR: d 177.8 (C-4), 152.1 (C-2), 142.1 (C-20), 140.8 (C-8a),
132.0 (C-7),131.1 (NeCH2eCH]CH2),126.6 (C-4a),126.4 (C-5),123.2
(C-10), 123.2 (C-6), 117.4 (NeCH2eCH]CH2), 115.9 (C-8), 109.2 (C-3),
49.9 (NeCH2eCH]CH2), 32.9 (C-30), 31.6 (C-70), 29.0 (C-60), 28.9
(C-50), 28.5 (C-40), 22.5 (C-80), 13.9 (C-90). ESI-MS m/z (%): [M þ 1]þ
310 (100), 268, 254, 240, 224, 210, 198, 184, 159, 109.
4.2.3.4. 1-(2-Propynyl)-2-[(1E)-nonenyl]-4-(1H)-quinolone (16d). Prepared
from (E)-3-undecen-2-one (4) (1.0 g, 5.9 mmol) in THF (20mL), LDA
(3.0 mL, 5.9 mmol) and N-2-propynyl isatoic acid anhydride (13)
(0.90 g, 4.5 mmol) in THF (20 mL).16dwas formed as a light yellow
solid (0.73 g, 53%), m.p.118e120 C. IR (KBr, nmax cm1): 3423, 3219,
2925, 2853, 2116, 1620, 1596, 1487, 1422, 761. 1H NMR: d 8.37 (dd,
J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.64 (td, J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.56 (d,
J ¼ 8.4 Hz, 1H, H-8), 7.33 (t, J ¼ 7.6 Hz, 1H, H-6), 6.47 (d, J ¼ 15.6 Hz,
1H, H-10), 6.39 (dt, J ¼ 15.6, 6.8, Hz, 1H, H-20), 6.34 (s, 1H, H-3), 4.81
(d, 4J ¼ 2.4 Hz, 2H, NeCH2eChCH), 2.47 (t, 4J ¼ 2.4 Hz, 1H,
NeCH2eChCH), 2.27 (q, J¼ 7.2 Hz, 2H, H-30), 1.49 (quint, J¼ 7.2 Hz,
2H, H-40), 1.32e1.24 (m, 8H, H-50e80), 0.87 (t, J ¼ 6.8 Hz, 3H, H-90).
13C NMR: d 177.9 (C-4), 151.5 (C-2), 142.8 (C-20), 140.5 (C-8a), 132.3
(C-7), 126.8 (C-4a), 126.6 (C-5), 123.5 (C-10), 122.9 (C-6), 115.5 (C-8),
109.6 (C-3), 76.9 (NeCH2eChCH), 74.8 (NeCH2eChCH), 38.0
(NeCH2eChCH), 33.1 (C-30), 31.7 (C-70), 29.0 (C-60), 29.0 (C-50),
28.5 (C-40), 22.5 (C-80), 13.9 (C-90). ESI-MS m/z (%): [M þ 1]þ 308
(100), 280 [M þ 2eC2H5]þ, 266, 236, 224, 210, 198, 184, 160, 107, 93.
4.2.3.5. 1-Butyl-2-[(1E)-nonenyl]-4-(1H)-quinolinone (16e). Prepared
from (E)-3-undecen-2-one (4) (1.0 g, 5.9 mmol) in THF (20mL), LDA
(3.0 mL, 5.9 mmol) and N-butyl isatoic acid anhydride (14) (0.99 g,
4.5mmol) in THF (20mL).16ewas formed as light yellow oil (0.77 g,
53%). IR (KBr, nmax cm1): 3421, 2927, 2855, 1623, 1598, 1486, 1423,
759. 1H NMR: d 8.41 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.61 (td, J ¼ 8.0,1.6 Hz,1H, H-7), 7.43 (d, J¼ 8.4 Hz,1H, H-8), 7.31 (t, J¼ 7.6 Hz,1H, H-
6), 6.41 (d, J ¼ 15.6 Hz, 1H, H-10), 6.37 (s, 1H, H-3), 6.33 (dt, J ¼ 15.6,
6.8Hz,1H,H-20), 4.11 (t, J¼8.4Hz, 2H,NeCH2e(CH2)2eCH3), 2.25 (q,
J ¼ 7.2 Hz, 2H, H-30), 1.77 (quint, J ¼ 7.6 Hz, 2H,
NeCH2eCH2eCH2eCH3), 1.45 (quint, J ¼ 6.8 Hz, 2H, H-40), 1.41 (m,
2H, Ne(CH2)2eCH2eCH3), 1.30e1.21 (m, 8H, H-50e80), 0.99 (t,
J¼ 7.2Hz, 3H,Ne(CH2)3eCH3), 0.87 (t, J¼ 6.8Hz, 3H, H-90). 13CNMR:
d 177.5 (C-4), 151.9 (C-2), 141.9 (C-20), 140.4 (C-8a), 131.9 (C-7), 126.8
(C-4a), 126.7 (C-5), 123.5 (C-10), 123.1 (C-6), 115.4 (C-8), 109.6 (C-3),
47.3 (NeCH2e(CH2)2eCH3), 33.0 (C-30), 31.7 (C-70), 30.6
(NeCH2eCH2eCH2eCH3), 29.0 (C-60), 29.0 (C50), 28.5 (C-40), 22.5
(C-80),19.8 (Ne(CH2)2eCH2eCH3),13.9 (C-90),13.6 (Ne(CH2)3eCH3).
ESI-MS m/z (%): [M þ 1]þ 326 (100), 270 [M þ 2eC4H9]þ, 242, 226,
198, 172, 159, 130, 117, 107.
4.2.3.6. 1-Ethyl-2-[(1E)-decenyl]-4-(1H)-quinolone (17a). Prepared
from (E)-3-dodecen-2-one (4) (1.0 g, 5.5 mmol) in THF (20 mL), LDA
(2.7 mL, 5.5 mmol) and N-ethyl isatoic anhydride (10) (0.79 g,
4.1 mmol) in THF (20 mL). 17a was formed as a light yellow semi-
solid (0.52 g, 41%). IR (KBr, nmax cm1): 3423, 2926, 2854, 1624,
1597, 1487, 1424, 1189, 1120, 722, 542. 1H NMR: d 8.43 (d, J ¼ 7.6 Hz,
1H, H-5), 7.64 (t, J ¼ 7.6 Hz, 1H, H-7), 7.44 (d, J ¼ 8.0 Hz, 1H, H-8),
7.31 (t, J ¼ 7.6 Hz, 1H, H-6), 6.42 (d, J ¼ 15.6 Hz, 1H, H-10), 6.37 (dt,
J ¼ 15.6, 6.8 Hz, 1H, H-20), 6.36 (s, 1H, H-3), 4.20 (q, J ¼ 6.2 Hz, 2H,
NeCH2eCH3), 2.26 (q, J ¼ 6.8 Hz, 2H, H-30), 1.49 (quint, J ¼ 6.8 Hz,
2H, H-40), 1.41 (t, J ¼ 7.2 Hz, 3H, NeCH2eCH3), 1.32e1.22 (m, 10H,
H-50e90), 0.86 (t, J¼ 6.8 Hz, 3H, H-100). 13C NMR: d 177.8 (C-4), 151.6
(C-2), 141.8 (C-20), 140.2 (C-8a), 132.0 (C-7), 127.0 (C-4a),126.8 (C-5),
123.3 (C-10), 123.0 (C-6), 115.2 (C-8), 109.7 (C-3), 42.3
(NeCH2eCH3), 33.1 (C-30), 31.8 (C-80), 29.3 (C-70), 29.2 (C-60), 29.1
(C-50), 28.6 (C-40), 22.6 (C-90), 14.0 (C-100), 13.9 (NeCH2eCH3). ESI-
MSm/z (%): [M þ 1]þ 312 (100), 284 [M þ 2eC2H5]þ, 270, 254, 226,
212, 198, 186, 172, 159, 146, 120, 93.
4.2.3.7. 1-Propyl-2-[(1E)-decenyl]-4-(1H)-quinolone (17b). Prepared
from (E)-3-dodecen-2-one (5) (1.0 g, 5.5 mmol) in THF (20 mL), LDA
(2.7 mL, 5.5 mmol) and N-propyl isatoic acid anhydride (11) (0.84 g,
4.1mmol) in THF (20mL).17bwas formed as yellowoil (0.60 g, 45%).
IR (KBr, nmax cm1): 3422, 2926, 2854, 1624, 1598, 1486, 1422, 759,
542. 1H NMR: d 8.43 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.61 (td, J ¼ 7.6,
1.6 Hz,1H, H-7), 7.43 (d, J¼ 8.4 Hz,1H, H-8), 7.32 (t, J¼ 7.6 Hz,1H, H-
6), 6.42 (d, J ¼ 15.2 Hz, 1H, H-10), 6.35 (s, 1H, H-3), 6.33 (dt, J ¼ 15.2,
6.8 Hz, 1H, H-20), 4.07 (t, J ¼ 8.0 Hz, 2H, NeCH2eCH2eCH3), 2.26 (q,
J ¼ 6.8 Hz, 2H, H-30), 1.82 (m, 2H, NeCH2eCH2eCH3), 1.49 (quint,
J¼7.2Hz, 2H,H-40),1.31e1.22 (m,10H,H-50e90),1.01 (t, J¼7.2Hz, 3H,
Ne(CH2)2eCH3), 0.88 (t, J¼6.8Hz, 3H,H-100). 13CNMR: d177.8 (C-4),
151.9 (C-2), 141.7 (C-20), 140.5 (C-8a), 131.9 (C-7), 127.0 (C-4a), 126.8
(C-5), 123.6 (C-10), 123.0 (C-6), 115.4 (C-8), 109.8 (C-3), 48.9
(NeCH2eCH2eCH3), 33.1 (C-30), 31.8 (C-80), 29.3 (C-70), 29.2 (C-
60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-90), 21.9 (NeCH2eCH2eCH3),
14.0 (C-100), 10.9 (Ne(CH2)2eCH3). ESI-MS m/z (%): [M þ 1]þ
326 (100), 284 [M þ 2eC3H7]þ, 270, 254, 242, 212, 186, 172, 159,
130, 106.
4.2.3.8. 1-(2-Propenyl)-2-[(1E)-decenyl]-4-(1H)-quinolone (17c). Prepared
from (E)-3-dodecen-2-one (5) (1.0 g, 5.5 mmol) in THF (20 mL), LDA
(2.7 mL, 5.5 mmol) and N-2-propenyl isatoic acid anhydride (12)
(0.83 g, 4.1 mmol) in THF (20mL).17cwas formed as light yellow oil
(0.55 g, 42%). IR (KBr, nmax cm1): 3420, 2925, 2854, 1623, 1598,
1486, 1422, 760. 1H NMR: d 8.39 (d, J ¼ 8.0 Hz, 1H, H-5), 7.56 (t,
J ¼ 7.2 Hz, 1H, H-7), 7.33 (d, J ¼ 8.4 Hz, 1H, H-8), 7.29 (t, J ¼ 7.6 Hz,
1H, H-6), 6.38 (s, 1H, H-3), 6.35 (dt, J ¼ 15.6, 6.8 Hz, 1H, H-20), 6.26
(d, J ¼ 15.6 Hz, 1H, H-10), 6.00 (ddt, J ¼ 17.2, 10.0, 4.0 Hz, 1H,
NeCH2eCH]CH2), 5.27 (d, J ¼ 10.0 Hz, 1H, NeCH2eCH]CHHb),
5.00 (d, J ¼ 17.2 Hz, 1H, NeCH2eCH]CHaH), 4.73 (d, J ¼ 2.0 Hz, 2H,
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J ¼ 6.8 Hz, 2H, H-40), 1.31e1.21 (m, 10H, H-50e90), 0.86 (t, J ¼ 6.8 Hz,
3H, H-100). 13C NMR: d 177.9 (C-4), 152.1 (C-2), 142.0 (C-20), 140.8
(C-8a), 132.0 (C-7), 131.1 (NeCH2eCH]CH2), 126.7 (C-4a), 126.4
(C-5), 123.3 (C-10), 123.1 (C-6), 117.4 (NeCH2eCH]CH2), 115.9 (C-8),
109.3 (C-3), 50.0 (NeCH2eCH]CH2), 33.0 (C-30), 31.8 (C-80), 29.3
(C-70), 29.1 (C-60), 29.0 (C-50), 28.5 (C-40), 22.6 (C-90), 14.0 (C-100).
ESI-MS m/z (%): [M þ 1]þ 324 (100), 282 [M þ 2eC3H5]þ, 254, 240,
224, 210, 198, 184, 172, 159, 146, 109, 95.
4.2.3.9. 1-(2-Propynyl)-2-[(1E)-decenyl]-4-(1H)-quinolone (17d). Prepared
from (E)-3-dodecen-2-one (5) (1.0 g, 5.5 mmol) in THF (20mL), LDA
(2.7 mL, 5.5 mmol) and N-2-propynyl isatoic acid anhydride (13)
(0.82 g, 4.1 mmol) in THF (20 mL).17dwas formed as a light yellow
solid (0.60 g, 46%), m.p. 79e91 C. IR (KBr, nmax cm1): 3445, 3188,
2925, 2854, 2115, 1617, 1593, 1562, 1485, 1422, 1272, 759. 1H NMR:
d 8.39 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.67 (td, J ¼ 8.0, 1.6 Hz, 1H, H-7),
7.58 (d, J ¼ 8.4 Hz, 1H, H-8), 7.35 (t, J ¼ 7.2 Hz, 1H, H-6), 6.49 (d,
J¼ 15.2 Hz, 1H, H-10), 6.40 (dt, J¼ 15.2, 6.8 Hz, 1H, H-20), 6.36 (s, 1H,
H-3), 4.82 (d, 4J ¼ 2.4 Hz, 2H, NeCH2eChCH), 2.48 (t, 4J ¼ 2.4 Hz,
1H, NeCH2eChCH), 2.29 (q, J ¼ 6.8 Hz, 2H, H-30), 1.50 (quint,
J ¼ 7.2 Hz, 2H, H-40), 1.34e1.22 (m, 10H, H-50e90), 0.88 (t, J ¼ 6.8 Hz,
3H, H-100). 13C NMR: d 178.0 (C-4), 151.6 (C-2), 142.8 (C-20), 140.5
(C-8a), 132.3 (C-7), 126.7 (C-4a), 126.6 (C-5), 123.5 (C-10), 123.0
(C-6), 115.5 (C-8), 109.7 (C-3), 76.9 (NeCH2eChCH), 74.8
(NeCH2eChCH), 38.0 (NeCH2eChCH), 33.1 (C30), 31.8 (C-80), 29.3
(C-70), 29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-90), 14.0 (C-100).
ESI-MS m/z (%): [M þ 1]þ 322 (100), 282 [M þ 2eC3H3]þ, 268, 230,
224, 210, 198, 184, 160, 107, 95.
4.2.3.10. 1-Butyl-2-[(1E)-decenyl]-4-(1H)-quinolone (17e). Prepared
from (E)-3-dodecen-2-one (5) (1.0 g, 5.5 mmol) in THF (20mL), LDA
(2.7 mL, 5.5 mmol) and N-butyl isatoic acid anhydride (14) (0.90 g,
4.1mmol) in THF (20mL).17ewas formed as yellowoil (0.52 g, 37%).
IR (KBr, nmax cm1): 3422, 2926, 2854,1623,1598,1485,1422, 759.1H
NMR: d8.42 (dd, J¼8.0,1.6Hz,1H,H-5), 7.61 (td, J¼8.0,1.6Hz,1H,H-
7), 7.43 (d, J ¼ 8.4 Hz, 1H, H-8), 7.31 (t, J ¼ 7.2 Hz, 1H, H-6), 6.41 (d,
J¼15.6Hz,1H,H-10), 6.34 (s,1H,H-3), 6.33 (dt, J¼15.6, 6.8Hz,1H,H-
20), 4.10 (t, J ¼ 8.0 Hz, 2H, NeCH2e(CH2)2eCH3), 2.25 (q, J ¼ 6.8 Hz,
2H, H-30), 1.77 (quint, J ¼ 7.6 Hz, 2H, NeCH2eCH2eCH2eCH3),
1.49e1.40 (m, 4H, H-40, Ne(CH2)2eCH2eCH3), 1.31e1.21 (m,10H, H-
50e90), 1.00 (t, J¼ 7.2 Hz, 3H, Ne(CH2)3eCH3), 0.87 (t, J¼ 6.8 Hz, 3H,
H-100). 13C NMR: d 177.7 (C-4), 151.8 (C-2), 141.7 (C-20), 140.4 (C-8a),
131.9 (C-7), 127.0 (C-4a), 126.8 (C-5), 123.6 (C-10), 123.0 (C-6), 115.4
(C-8),109.7 (C-3), 47.3 (NeCH2e(CH2)2eCH3), 33.0 (C-30), 31.8 (C-80),
30.6 (NeCH2eCH2eCH2eCH3), 29.3 (C-70), 29.2 (C-60), 29.1 (C-50),
28.6 (C-40), 22.6 (C-90), 19.9 (Ne(CH2)2eCH2eCH3), 14.0 (C-100), 13.6
(Ne(CH2)3eCH3). ESI-MS m/z (%): [M þ 1]þ 340 (100), 284
[M þ 2eC4H9]þ, 256, 242, 226, 198, 172, 159, 117, 105.
4.2.3.11. 1-Pentyl-2-[(1E)-decenyl]-4-(1H)-quinolone (17f). Prepared
from (E)-3-dodecen-2-one (5) (1.0 g, 5.5 mmol) in THF (20 mL), LDA
(2.7 mL, 5.5 mmol) and N-pentyl isatoic acid anhydride (15) (0.96 g,
4.1 mmol) in THF (20 mL). 17fwas formed as light yellow oil (0.65 g,
45%). IR (KBr, nmax cm1): 3423, 2926, 2855, 1623, 1598, 1487, 1424,
759.1HNMR: d8.44 (dd, J¼8.0,1.6Hz,1H,H-5), 7.62 (td, J¼8.0,1.6Hz,
1H, H-7), 7.44 (d, J¼ 8.4 Hz,1H, H-8), 7.33 (t, J¼ 7.2 Hz,1H, H-6), 6.42
(d, J¼ 15.6 Hz,1H, H-10), 6.36 (s,1H, H-3), 6.34 (dt, J¼ 15.6, 6.8 Hz,1H,
H-20), 4.11 (t, J¼ 8.0 Hz, 2H,NeCH2e(CH2)3eCH3), 2.27 (q, J¼ 6.8 Hz,
2H, H-30), 1.80 (m, 2H, NeCH2eCH2e(CH2)2eCH3), 1.48 (quint,
J ¼ 7.2 Hz, 2H, H-40), 1.41e1.39 (m, 4H, Ne(CH2)2eCH2eCH2eCH3),
1.32e1.22 (m, 10H, H-50e90), 0.94 (t, J ¼ 6.8 Hz, 3H, Ne(CH2)4eCH3),
0.87 (t, J¼ 6.8 Hz, 3H, H-100). 13C NMR: d 177.8 (C-4),151.8 (C-2),141.7
(C-20), 140.5 (C-8a), 132.0 (C-7), 127.1 (C-4a), 126.9 (C-5), 123.6 (C-10),
123.1 (C-6), 115.4 (C-8), 109.8 (C-3), 47.5 (NeCH2e(CH2)3eCH3), 33.1(C-30), 31.8 (C-80), 29.4 (C-70), 29.2 (C-60), 29.1 (C-50), 28.8
(NeCH2eCH2e(CH2)2eCH3),28.6(C-40),28.3(Ne(CH2)2eCH2eCH2eCH3),
22.6 (C-90), 22.3 (Ne(CH2)3eCH2eCH3), 14.0 (C-100), 13.9
(Ne(CH2)4eCH3). ESI-MS m/z (%): [M þ 1]þ 354 (100), 284
[M þ 2eC5H11]þ, 256, 240, 214, 198, 184, 172, 159.
4.2.3.12. 1-Ethyl-2-[(1E)-undecenyl]-4-(1H)-quinolone (18a). Prepared
from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in THF (25 mL), LDA
(3.3 mL, 6.6 mmol) and N-ethyl isatoic acid anhydride (10) (0.96 g,
5.0 mmol) in THF (20 mL). 18a was formed as a yellow semisolid
(0.59 g, 36%). IR (KBr, nmax cm1): 3421, 2925, 2853, 1625, 1597,
1486, 1424, 1189, 1119, 759, 722, 543. 1H NMR: d 8.45 (d, J ¼ 8.0 Hz,
1H, H-5), 7.65 (t, J ¼ 8.0 Hz, 1H, H-7), 7.51 (d, J ¼ 8.0 Hz, 1H, H-8),
7.36 (t, J¼ 6.8 Hz,1H, H-6), 6.48 (d, J¼ 15.2 Hz,1H, H-10), 6.43 (s, 1H,
H-3), 6.40 (dt, J ¼ 15.2, 6.8 Hz, 1H, H-20), 4.25 (q, J ¼ 6.8 Hz, 2H,
NeCH2eCH3), 2.28 (q, J ¼ 6.8 Hz, 2H, H-30), 1.50 (m, 2H, H-40), 1.45
(t, J ¼ 6.8 Hz, 3H, NeCH2eCH3), 1.37e1.22 (m, 12H, H-50e100), 0.88
(t, J¼ 6.8 Hz, 3H, H-110). 13C NMR: d 177.4 (C-4),151.9 (C-2),142.4 (C-
20), 140.2 (C-8a), 132.2 (C-7), 126.9 (C-4a), 126.8 (C-5), 123.3 (C-10),
123.1 (C-6), 115.3 (C-8), 109.5 (C-3), 42.5 (NeCH2eCH3), 33.2 (C-30),
31.8 (C-90), 29.5 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.6
(C-40), 22.6 (C-100), 14.1 (C-110), 13.9 (NeCH2eCH3). ESI-MS m/z
(%): [M þ 1]þ 326 (100), 298, 254, 240, 212, 198, 186, 172, 159, 118,
104, 93.
4.2.3.13. 1-Propyl-2-[(1E)-undecenyl]-4-(1H)-quinolone (18b). Prepared
from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in THF (25 mL), LDA
(3.3 mL, 6.6 mmol) and N-propyl isatoic acid anhydride (11) (1.02 g,
5.0 mmol) in THF (20 mL). 18b was formed as light yellow oil
(0.68 g, 40%). IR (KBr, nmax cm1): 3421, 2925, 2854, 1624, 1599,
1486, 1422, 759. 1H NMR: d 8.44 (d, J ¼ 8.0 Hz, 1H, H-5), 7.64 (t,
J ¼ 8.0 Hz, 1H, H-7), 7.45 (d, J ¼ 8.4 Hz, 1H, H-8), 7.35 (t, J ¼ 7.6 Hz,
1H, H-6), 6.43 (s, 1H, H-3), 6.42 (d, J ¼ 14.8 Hz, 1H, H-10), 6.37 (dt,
J¼ 14.8, 6.4 Hz, 1H, H-20), 4.10 (t, J¼ 8.0 Hz, 2H, NeCH2eCH2eCH3),
2.27 (q, J ¼ 6.8 Hz, 2H, H-30), 1.84 (m, 2H, NeCH2eCH2eCH3), 1.50
(m, 2H, H-40), 1.37e1.21 (m, 12H, H-50e100), 1.04 (t, J ¼ 7.2 Hz, 3H,
Ne(CH2)2eCH3), 0.88 (t, J ¼ 7.2 Hz, 3H, H-110). 13C NMR: d 177.4 (C-
4), 152.1 (C-2), 142.2 (C-20), 140.4 (C-8a), 132.1 (C-7), 126.8 (C-4a),
126.7 (C-5), 123.5 (C-10), 123.3 (C-6), 115.5 (C-8), 109.6 (C-3), 49.1
(NeCH2eCH2eCH3), 33.1 (C-30), 31.8 (C-90), 29.5 (C-80), 29.4 (C-70),
29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-100), 22.0
(NeCH2eCH2eCH3), 14.0 (C-110), 11.0 (Ne(CH2)2eCH3). ESI-MS m/z
(%): [Mþ 1]þ 340 (100), 298 [Mþ 2eC3H7]þ, 254, 228,198, 172,159,
117, 103.
4.2.3.14. 1-(2-Propenyl)-2-[(1E)-undecenyl]-4-(1H)-quinolone
(18c). Prepared from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in
THF (25 mL), LDA (3.3 mL, 6.6 mmol) and N-2-propenyl isatoic acid
anhydride (12) (1.01 g, 5.0 mmol) in THF (20mL).18cwas formed as
yellow oil (0.71 g, 42%). IR (KBr, nmax cm1): 3444, 2925, 2853,1624,
1599, 1487, 1421, 760. 1H NMR: d 8.40 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5),
7.58 (td, J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.36 (d, J ¼ 8.4 Hz, 1H, H-8), 7.31 (t,
J¼ 7.6 Hz,1H, H-6), 6.42 (s, 1H, H-3), 6.39 (dt, J¼ 15.2, 6.8 Hz,1H, H-
20), 6.31 (d, J¼ 15.2 Hz, 1H, H-10), 6.03 (ddt, J¼ 17.2, 10.8, 4.0 Hz, 1H,
NeCH2eCH]CH2), 5.30 (d, J ¼ 10.8 Hz, 1H, NeCH2eCH]CHHb),
4.99 (d, J¼ 17.2 Hz, 1H, NeCH2eCH]CHaH), 4.75 (dt, J¼ 4.0, 1.6 Hz,
2H, NeCH2eCH]CH2), 2.23 (q, J ¼ 6.8 Hz, 2H, H-30), 1.47 (quint,
J¼ 7.2 Hz, 2H, H-40), 1.31e1.23 (m,12H, H-50e100), 0.87 (t, J¼ 6.8 Hz,
3H, H-110). 13C NMR: d 177.8 (C-4), 152.2 (C-2), 142.2 (C-20), 140.8 (C-
8a), 132.1 (C-7), 131.1 (NeCH2eCH]CH2), 126.6 (C-4a), 126.5 (C-5),
123.2 (C-10), 123.2 (C-6), 117.5 (NeCH2eCH]CH2), 115.9 (C-8), 109.3
(C-3), 50.0 (NeCH2eCH]CH2), 33.0 (C-30), 31.8 (C-90), 29.5 (C-80),
29.4 (C-70), 29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-100), 14.0
(C-110). ESI-MSm/z (%): [M þ 1]þ 338 (100), 296, 240, 224, 210, 198,
184, 172, 159, 109, 95.
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(18d). Prepared from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in
THF (25 mL), LDA (3.3 mL, 6.6 mmol) and N-2-propynyl isatoic acid
anhydride (13) (1.0 g, 5.0 mmol) in THF (20 mL). 18dwas formed as
a light yellowsolid (0.67g, 40%),m.p.115e117 C. IR (KBr,nmaxcm1):
3445, 3224, 2922, 2849, 2118, 1620, 1597, 1489, 1422, 764, 711. 1H
NMR: d 8.41 (d, J ¼ 8.0 Hz, 1H, H-5), 7.69 (t, J ¼ 8.0 Hz, 1H, H-7),
7.60 (d, J ¼ 8.4 Hz, 1H, H-8), 7.38 (t, J ¼ 7.6 Hz, 1H, H-6), 6.51
(d, J ¼ 15.6 Hz, 1H, H-10), 6.44 (dt, J ¼ 15.6, 6.4 Hz, 1H, H-20), 6.43
(s, 1H, H-3), 4.85 (d, 4J ¼ 2.4 Hz, 2H, NeCH2eChCH), 2.48 (bs, 1H,
NeCH2eChCH), 2.30 (q, J ¼ 6.8 Hz, 2H, H-30), 1.52 (quint,
J ¼ 7.2 Hz, 2H, H-40), 1.32e1.23 (m, 12H, H-50e100), 0.88 (t,
J ¼ 6.8 Hz, 3H, H-110). 13C NMR: d 177.9 (C-4), 151.7 (C-2), 143.1 (C-
20), 140.5 (C-8a), 132.4 (C-7), 126.7 (C-4a), 126.5 (C-5), 123.7 (C-10),
122.9 (C-6), 115.5 (C-8), 109.6 (C-3), 76.8 (NeCH2eChCH), 74.9
(NeCH2eChCH), 38.1 (NeCH2eChCH), 33.1 (C-30), 31.8 (C-90),
29.5 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.5 (C-40), 22.6 (C-
110), 14.0 (C-110). ESI-MS m/z (%): [M þ 1]þ 336 (100), 294, 236,
224, 210, 196, 182, 160, 107, 95.
4.2.3.16. 1-Butyl-2-[(1E)-undecenyl]-4-(1H)-quinolone (18e). Prepared
from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in THF (25 mL), LDA
(3.3 mL, 6.6 mmol) and N-butyl isatoic acid anhydride (14) (1.09 g,
5.0mmol) inTHF (20mL).18ewas formed as yellowoil (0.74 g, 42%). IR
(KBr, nmax cm1): 3424, 2926, 2854, 1624, 1598, 1486, 1423, 1177, 759.
1H NMR: d 8.43 (d, J ¼ 8.4 Hz, 1H, H-5), 7.63 (t, J ¼ 8.4 Hz, 1H, H-7),
7.45 (d, J ¼ 8.4 Hz, 1H, H-8), 7.33 (t, J ¼ 7.6 Hz, 1H, H-6), 6.42 (d,
J ¼ 15.6 Hz, 1H, H-10), 6.41 (s, 1H, H-3), 6.35 (dt, J ¼ 15.6, 6.0 Hz, 1H,
H-20), 4.13 (t, J ¼ 8.0 Hz, 2H, NeCH2e(CH2)2eCH3), 2.27 (q, J ¼ 7.6 Hz,
2H, H-30), 1.79 (quint, J ¼ 7.6 Hz, 2H, NeCH2eCH2eCH2eCH3), 1.48
(quint, J ¼ 7.2 Hz, 2H, H-40), 1.44 (m, 2H, Ne(CH2)2eCH2eCH3),
1.31e1.22 (m, 12H, H-50e100), 1.01 (t, J ¼ 7.2 Hz, 3H, Ne(CH2)3eCH3),
0.87 (t, J¼ 6.8 Hz, 3H, H-110). 13C NMR: d 177.5 (C-4), 152.0 (C-2), 142.0
(C-20), 140.4 (C-8a), 132.0 (C-7), 126.9 (C-4a), 126.8 (C-5), 123.5 (C-10),
123.2 (C-6), 115.4 (C-8), 109.7 (C-3), 47.4 (NeCH2e(CH2)2eCH3), 33.1
(C-30), 31.8 (C-90), 30.6 (NeCH2eCH2eCH2eCH3), 29.5 (C-80), 29.4 (C-
70), 29.3 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-100), 19.9
(Ne(CH2)2eCH2eCH3), 14.0 (C-140), 13.7 (Ne(CH2)3eCH3). ESI-MSm/z
(%): [M þ 1]þ 354 (100), 298 [M þ 2eC4H9]þ, 256, 242, 228, 198, 172,
159, 130, 106.
4.2.3.17. 1-Pentyl-2-[(1E)-undecenyl]-4-(1H)-quinolone (18f). Prepared
from (E)-3-tridecen-2-one (6) (1.3 g, 6.6 mmol) in THF (25 mL),
LDA (3.3 mL, 6.6 mmol) and N-pentyl isatoic acid anhydride (15)
(1.16 g, 5.0 mmol) in THF (20 mL). 18f was formed as light yellow oil
(0.70 g, 38%). IR (KBr, nmax cm1): 3422, 2926, 2854, 1624, 1598, 1487,
1423, 759. 1H NMR: d 8.45 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.66 (td,
J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.48 (d, J ¼ 8.4 Hz, 1H, H-8), 7.37 (t, J ¼ 7.2 Hz,
1H, H-6), 6.51 (s, 1H, H-3), 6.45 (d, J ¼ 15.2 Hz, 1H, H-10), 6.40 (dt,
J¼ 15.2, 6.8 Hz, 1H, H-20), 4.15 (t, J¼ 8.4 Hz, 2H, NeCH2e(CH2)3eCH3),
2.29 (q, J ¼ 7.2 Hz, 2H, H-30), 1.83 (m, 2H, NeCH2eCH2e(CH2)2eCH3),
1.51 (quint, J ¼ 6.8 Hz, 2H, H-40), 1.44e1.41 (m, 4H,
Ne(CH2)2eCH2eCH2eCH3), 1.33e1.22 (m, 12H, H-50-100), 0.95 (t,
J ¼ 6.8 Hz, 3H, Ne(CH2)4eCH3), 0.88 (t, J ¼ 6.8 Hz, 3H, H-110). 13C
NMR: d 177.6 (C-4), 152.2 (C-2), 142.4 (C-20), 140.4 (C-8a), 132.2 (C-7),
126.9 (C-4a), 126.8 (C-5), 123.4 (C-10), 123.2 (C-6), 115.5 (C-8), 109.5 (C-
3), 47.7 (NeCH2e(CH2)3eCH3), 33.2 (C-30), 31.9 (C-90), 29.5 (C-80), 29.4
(C-70), 29.3 (C-60), 29.2 (C-50), 28.8 (NeCH2eCH2e(CH2)2eCH3), 28.6
(C-40), 28.3 (Ne(CH2)2eCH2eCH2eCH3), 22.6 (C-100), 22.3
(Ne(CH2)3eCH2eCH3), 14.1 (C-110), 13.9 (Ne(CH2)4eCH3). ESI-MS m/z
(%): [M þ 1]þ 368 (100), 296 [M þ 2eC5H11]þ, 281, 268, 256, 228, 198,
184, 172, 159.
4.2.3.18. 1-Ethyl-2-[(1E)-dodecenyl]-4-(1H)-quinolone (19a). Prepared
from (E)-3-tetradecen-2-one (7) (1.3 g, 6.2 mmol) in THF (25mL), LDA(3.1 mL, 6.1 mmol) and N-ethyl isatoic acid anhydride (10) (0.89 g,
4.6 mmol) in THF (20 mL).19awas formed as a light yellow semisolid
(0.68 g, 44%). IR (KBr, nmax cm1): 3420, 2925, 2853, 1623, 1597, 1488,
1424, 759. 1HNMR: d 8.43 (d, J¼ 8.0 Hz,1H, H-5), 7.63 (t, J¼ 8.0Hz,1H,
H-7), 7.48 (d, J ¼ 7.2 Hz, 1H, H-8), 7.32 (t, J ¼ 7.2 Hz, 1H, H-6), 6.42 (d,
J¼ 15.2 Hz,1H, H-10), 6.40 (s,1H, H-3), 6.35 (dt, J¼ 15.2, 6.4 Hz,1H, H-
20), 4.21 (q, J¼ 6.4 Hz, 2H, NeCH2eCH3), 2.26 (q, J¼ 6.4 Hz, 2H, H-30),
1.49 (m, 2H, H-40), 1.42 (t, J ¼ 6.4 Hz, 3H, NeCH2eCH3), 1.38e1.22 (m,
14H, H-50e110), 0.86 (t, J ¼ 6.4 Hz, 3H, H-120). 13C NMR: d 177.6 (C-4),
151.7 (C-2),142.1 (C-20),140.2 (C-8a),132.1 (C-7),126.9 (C-4a),126.8 (C-
5),123.2 (C-10),123.1 (C-6),115.3 (C-8),109.6 (C-3), 42.4 (NeCH2eCH3),
33.1 (C-30), 31.8 (C-100), 29.5 (C-90), 29.5 (C-80), 29.4 (C-70), 29.2 (C-60),
29.1 (C-50), 28.6 (C-40), 22.6 (C-110), 14.0 (C-120), 13.9 (NeCH2eCH3).
ESI-MS m/z (%): [M þ 1]þ 340 (100), 312 [M þ 2eC2H5]þ, 268, 254,
240, 214, 198, 186, 172, 159, 117.
4.2.3.19. 1-Propyl-2-[(1E)-dodecenyl]-4-(1H)-quinolone (19b). Prepared
from (E)-3-tetradecen-2-one (7) (1.3 g, 6.2 mmol) in THF (25 mL), LDA
(3.1 mL, 6.1 mmol) and N-propyl isatoic acid anhydride (11) (0.95 g,
4.6 mmol) in THF (20 mL). 19b was formed as light yellow oil (0.76 g,
47%). IR (KBr, nmax cm1): 3421, 2925, 2853,1624,1598,1486,1422, 759.
1H NMR: d 8.45 (dd, J¼ 8.0, 1.6 Hz,1H, H-5), 7.64 (td, J¼ 8.0, 1.6 Hz,1H,
H-7), 7.46 (d, J ¼ 8.4 Hz, 1H, H-8), 7.35 (t, J ¼ 7.2 Hz, 1H, H-6), 6.44 (d,
J¼ 15.2 Hz, 1H, H-10), 6.43 (s, 1H, H-3), 6.37 (dt, J¼ 15.2, 6.4 Hz, 1H, H-
20), 4.11 (t, J¼ 8.0 Hz, 2H,NeCH2eCH2eCH3), 2.28 (q, J¼ 6.8 Hz, 2H, H-
30), 1.85 (m, 2H, NeCH2eCH2eCH3), 1.50 (quint, J ¼ 6.8 Hz, 2H, H-40),
1.32e1.22 (m, 14H, H-50e110), 1.05 (t, J ¼ 7.2 Hz, 3H, Ne(CH2)2eCH3),
0.88 (t, J ¼ 6.8 Hz, 3H, H-120). 13C NMR: d 177.6 (C-4), 152.1 (C-2), 142.1
(C-20), 140.5 (C-8a), 132.1 (C-7), 126.9 (C-4a), 126.8 (C-5), 123.5 (C-10),
123.2 (C-6), 115.5 (C-8), 109.7 (C-3), 49.1 (NeCH2eCH2eCH3), 33.1 (C-
30), 31.9 (C-100), 29.6 (C-90), 29.6 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-
50), 28.6 (C-40), 22.6 (C-110), 22.0 (NeCH2eCH2eCH3), 14.0 (C-120), 10.9
(Ne(CH2)2eCH3). ESI-MS m/z (%): [M þ 1]þ 354 (100), 312
[M þ 2eC3H7]þ, 298, 254, 186, 172, 107.
4.2.3.20. 1-(2-Propenyl)-2-[(1E)-dodecenyl]-4-(1H)-quinolone
(19c). Prepared from (E)-3-tetradecen-2-one (7) (1.3 g, 6.2 mmol)
in THF (25 mL), LDA (3.1 mL, 6.2 mmol) and N-2-propenyl isatoic
acid anhydride (12) (0.94 g, 4.6 mmol) in THF (20 mL). 19c was
formed as a light yellow semisolid (0.66 g, 41%). IR (KBr, nmax cm1):
3419, 2925, 2853, 1625, 1599, 1486, 1422, 760. 1H NMR: d 8.41 (dd,
J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.59 (td, J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.36 (d,
J ¼ 8.4 Hz, 1H, H-8), 7.32 (t, J ¼ 7.6 Hz, 1H, H-6), 6.44 (s, 1H, H-3),
6.40 (dt, J ¼ 15.6, 6.4 Hz, 1H, H-20), 6.31 (d, J ¼ 15.6 Hz, 1H, H-10),
6.02 (ddt, J ¼ 17.2, 10.4, 4.0 Hz, 1H, NeCH2eCH]CH2), 5.30 (d,
J ¼ 10.4 Hz, 1H, NeCH2eCH]CHHb), 5.01 (d, J ¼ 17.2 Hz, 1H,
NeCH2eCH]CHaH), 4.76 (dt, J¼ 4.0,1.6 Hz, 2H,NeCH2eCH]CH2),
2.24 (q, J ¼ 6.8 Hz, 2H, H-30), 1.47 (quint, J ¼ 7.2 Hz, 2H, H-40),
1.36e1.22 (m, 14H, H-50e110), 0.86 (t, J ¼ 6.8 Hz, 3H, H-120). 13C
NMR: d 177.8 (C-4), 152.2 (C-2), 142.3 (C-20), 140.9 (C-8a), 132.1 (C-
7), 131.1 (NeCH2eCH]CH2), 126.6 (C-4a), 126.5 (C-5), 123.3 (C-10),
123.2 (C-6), 117.5 (NeCH2eCH]CH2), 116.0 (C-8), 109.3 (C-3), 50.1
(NeCH2eCH]CH2), 33.1 (C-30), 31.8 (C-100), 29.5 (C-90), 29.5 (C-80),
29.4 (C-70), 29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-110), 14.0 (C-
120). ESI-MS m/z (%): [M þ 1]þ 352 (100), 310 [M þ 2eC3H5]þ, 224,
210, 198, 184, 172, 146, 107.
4.2.3.21. 1-(2-Propynyl)-2-[(1E)-dodecenyl]-4-(1H)-quinolone
(19d). Prepared from (E)-3-tetradecen-2-one (7) (1.3 g, 6.2 mmol)
inTHF (25mL), LDA (3.1mL, 6.2mmol) andN-2-propynyl isatoic acid
anhydride (13) (0.93 g, 4.6mmol) in THF (20mL).19dwas formed as
a light yellow semisolid (0.70 g, 44%). IR (KBr, nmax cm1): 3445,
3182, 2922, 2847, 2112, 1623, 1598, 1487, 1418, 764. 1H NMR: d 8.39
(dd, J¼ 8.0,1.6 Hz,1H, H-5), 7.66 (td, J¼ 8.0, 1.6 Hz,1H, H-7), 7.58 (d,
J¼8.4Hz,1H,H-8), 7.35 (t, J¼7.6Hz,1H,H-6), 6.49 (d, J¼14.6Hz,1H,
A.A. Wube et al. / European Journal of Medicinal Chemistry 46 (2011) 2091e2101 2099H-10), 6.40 (dt, J ¼ 14.6, 6.8 Hz, 1H, H-20), 6.37 (s, 1H, H-3), 4.82 (d,
4J ¼ 2.4 Hz, 2H, NeCH2eChCH), 2.48 (t, 4J ¼ 2.4 Hz, 1H,
NeCH2eChCH), 2.29 (q, J¼ 6.8 Hz, 2H, H-30), 1.50 (quint, J¼ 7.2 Hz,
2H, H-40),1.36e1.22 (m,14H, H-50e110), 0.87 (t, J¼ 6.8 Hz, 3H, H-120)
13C NMR: d 177.9 (C-4), 151.6 (C-2), 142.8 (C-20), 140.5 (C-8a), 132.3
(C-7), 126.6 (C-4a), 126.6 (C-5), 123.6 (C-10), 122.9 (C-6), 115.9 (C-8),
109.7 (C-3), 76.9 (NeCH2eChCH), 74.8 (NeCH2eChCH), 38.1
(NeCH2eChCH), 33.1 (C-30), 31.8 (C-100), 29.5 (C-90), 29.5 (C-80),
29.4 (C-70), 29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-110), 14.0
(C-120). ESI-MSm/z (%): [Mþ 1]þ 350 (100), 310 [Mþ 2eC3H3]þ, 294,
280, 236, 224, 210, 198, 184, 160, 107.
4.2.3.22. 1-Butyl-2-[(1E)-dodecenyl]-4-(1H)-quinolone (19e). Prepared
from(E)-3-tetradecen-2-one (7) (1.3g, 6.2mmol) inTHF(25mL), LDA
(3.1 mL, 6.2 mmol) and N-butyl isatoic acid anhydride (14) (1.02 g,
4.6 mmol) in THF (20mL).19ewas formed as light yellow oil (0.81 g,
48%). IR (KBr, nmax cm1): 3424, 2925, 2854, 1623, 1598, 1486, 1423,
1176, 759.1HNMR: d8.44 (d, J¼8.4Hz,1H,H-5), 7.64 (t, J¼8.4Hz,1H,
H-7), 7.46 (d, J¼ 8.4 Hz, 1H, H-8), 7.34 (t, J¼ 7.6 Hz,1H, H-6), 6.44 (s,
1H,H-3), 6.37 (d, J¼ 16.0Hz,1H,H-10), 6.35 (dt, J¼ 16.0, 6.4Hz,1H,H-
20), 4.14 (t, J¼ 8.0 Hz, 2H,NeCH2e(CH2)eCH3), 2.27 (q, J¼ 7.2 Hz, 2H,
H-30),1.80 (quint, J¼ 7.6Hz, 2H,NeCH2eCH2eCH2eCH3),1.49 (quint,
J ¼ 7.2 Hz, 2H, H->40), 1.44 (m, 2H, Ne(CH2)2eCH2eCH3), 1.37e1.22
(m, 14H, H-50e110), 1.01 (t, J ¼ 7.6 Hz, 3H, Ne(CH2)3eCH3), 0.87 (t,
J¼ 6.8 Hz, 3H, H-120). 13C NMR: d 177.5 (C-4),151.9 (C-2),142.0 (C-20),
140.4 (C-8a), 132.0 (C-7), 126.8 (C-4a),126.8 (C-5), 123.5 (C-10), 123.2
(C-6),115.4 (C-8),109.6 (C-3), 47.3 (NeCH2e(CH2)2eCH3), 33.1 (C-30),
31.8 (C-100), 30.6 (NeCH2eCH2eCH2eCH3), 29.5 (C-90), 29.5 (C-80),
29.4 (C-70), 29.2 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-11), 19.9
(Ne(CH2)2eCH2eCH3),14.0 (C-140), 13.7(Ne(CH2)3eCH3). ESI-MSm/
z (%): [M þ 1]þ 368 (100), 312, 298, 284, 256, 242, 198, 172, 159, 117,
105.
4.2.3.23. 1-Pentyl-2-[(1E)-dodecenyl]-4-(1H)-quinolone (19f). Prepared
from (E)-3-tetradecen-2-one (7) (1.3 g, 6.2 mmol) in THF (25 mL), LDA
(3.1 mL, 6.2 mmol) and N-pentyl isatoic acid anhydride (15) (1.09 g,
4.6 mmol) in THF (20 mL). 19f was formed as a light yellow semisolid
(0.75 g, 43%). IR (KBr, nmax cm1): 3423, 2925, 2854, 1624, 1598, 1486,
1422, 759. 1H NMR: d 8.44 (dd, J¼ 8.0, 1.6 Hz,1H, H-5), 7.64 (td, J¼ 8.0,
1.6 Hz,1H, H-7), 7.45 (d, J¼ 8.4 Hz,1H, H-8), 7.34 (t, J¼ 7.6 Hz,1H, H-6),
6.42 (d, J¼ 15.6 Hz,1H, H-10), 6.39 (s,1H, H-3), 6.36 (dt, J¼ 15.6, 6.8 Hz,
1H, H-20), 4.11 (t, J ¼ 8.0 Hz, 2H, NeCH2e(CH2)3eCH3), 2.27
(q, J ¼ 6.8 Hz, 2H, H-30), 1.81 (m, 2H, NeCH2eCH2e(CH2)2eCH3),
1.50 (quint, J ¼ 6.8 Hz, 2H, H-40), 1.44e1.39 (m, 4H,
Ne(CH2)2eCH2eCH2eCH3), 1.32e1.23 (m, 14H, H-50e110), 0.94 (t,
J¼ 6.8 Hz, 3H,Ne(CH2)4eCH3), 0.87 (t, J¼ 6.8 Hz, 3H, H-120). 13C NMR:
d 177.6 (C-4), 151.9 (C-2), 142.0 (C-20), 140.4 (C-8a), 132.1 (C-7), 126.9 (C-
4a), 126.8 (C-5), 123.5 (C-10), 123.2 (C-6), 115.4 (C-8), 109.7 (C-3), 47.6
(NeCH2e(CH2)3eCH3), 33.1 (C-30), 31.9 (C-100), 29.6 (C-90), 29.6 (C-80),
29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.8 (NeCH2eCH2e(CH2)2eCH3),
28.6 (C-40), 28.3 (Ne(CH2)2eCH2eCH2eCH3), 22.6 (Ce110), 22.3
(Ne(CH2)3eCH2eCH3), 14.0 (C-120), 13.9 (Ne(CH2)4eCH3). ESI-MS m/z
(%): [M þ 1]þ 382 (100), 310 [M þ 2eC5H11]þ, 284, 256, 240, 198, 184,
159.
4.2.3.24. 1-Ethyl-2-[(1E)-tridecenyl]-4-(1H)-quinolone (20a). Prepared
from (E)-3-pentadecen-2-one (8) (1.5 g, 6.7mmol) inTHF (25mL), LDA
(3.4 mL, 6.7 mmol) and N-ethyl isatoic acid anhydride (10) (0.96 g,
5.0 mmol) in THF (20 mL). 20a was formed as a yellow semisolid
(0.79 g, 45%). IR (KBr, nmax cm1): 3422, 2925, 2853, 1626, 1597, 1487,
1423, 1177, 759. 1H NMR: d 8.44 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5), 7.65 (td,
J¼ 8.0, 1.6 Hz, 1H, H-7), 7.50 (d, J¼ 8.4 Hz, 1H, H-8), 7.34 (t, J¼ 7.6 Hz,
1H, H-6), 6.45 (d, J ¼ 15.2 Hz, 1H, H-10), 6.42 (s, 1H, H-3), 6.37 (dt,
J¼ 15.2, 6.4 Hz,1H, H-20), 4.25 (q, J¼ 6.4 Hz, 2H,NeCH2eCH3), 2.27 (q,
J ¼ 6.4 Hz, 2H, H-30), 1.49 (m, 2H, H-40), 1.44 (t, J ¼ 6.4 Hz, 3H,NeCH2eCH3), 1.38e1.21 (m, 16H, H-50e120), 0.87 (t, J ¼ 6.4 Hz, 3H, H-
130). 13C NMR: d 177.5 (C-4),151.8 (C-2),142.3 (C-20),140.2 (C-8a),132.2
(C-7), 126.9 (C-4a), 126.8 (C-5), 123.2 (C-10), 123.2 (C-6), 115.3 (C-8),
109.6 (C-3), 42.5 (NeCH2eCH3), 33.1 (C-30), 31.9(C-110), 29.6 (C-100),
29.6 (C-90), 29.5 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.6 (C-40),
22.6 (C-120), 14.1 (C-130), 13.9 (NeCH2eCH3). ESI-MSm/z (%): [Mþ 1]þ
354 (100), 326 [M þ 2eC2H5]þ, 312, 282, 268, 212, 198, 186, 172, 159,
117, 103.
4.2.3.25. 1-(2-Propenyl)-2-[(1E)-tridecenyl]-4-(1H)-quinolone
(20c). Prepared from (E)-3-pentadecen-2-one (8) (1.5 g, 6.7 mmol)
inTHF (25mL), LDA (3.4mL, 6.7mmol) andN-2-propenyl isatoic acid
anhydride (12) (1.02 g, 5.0mmol) in THF (20mL). 20cwas formed as
yellow oil (0.76 g, 42%). IR (KBr, nmax cm1): 3443, 2924, 2853, 1624,
1599, 1486, 1422, 759. 1H NMR: d 8.40 (dd, J ¼ 8.0, 1.6 Hz, 1H, H-5),
7.58 (td, J ¼ 8.0, 1.6 Hz, 1H, H-7), 7.35 (d, J ¼ 8.4 Hz, 1H, H-8), 7.31 (t,
J ¼ 7.6 Hz, 1H, H-6), 6.41 (s, 1H, H-3), 6.37 (dt, J ¼ 16.0, 6.4 Hz, 1H,
H-20), 6.31 (d, J¼16.0Hz,1H,H-10), 6.02 (ddt, J¼17.2,10.7, 4.0Hz,1H,
NeCH2eCH]CH2), 5.29 (d, J ¼ 10.8 Hz, 1H, NeCH2eCH]CHHb),
5.00 (d, J ¼ 17.2 Hz, 1H, NeCH2eCH]CHaH), 4.74 (d, J ¼ 2.0 Hz, 2H,
NeCH2eCH]CH2), 2.23 (q, J ¼ 6.8 Hz, 2H, H-30), 1.47 (m, 2H, H-40),
1.36e1.21 (m,16H, H-50e120), 0.86 (t, J¼ 6.8 Hz, 3H, H-130). 13CNMR:
d 177.9 (C-4), 152.2 (C-2), 142.2 (C-20), 140.9 (C-8a), 132.1 (C-7), 131.1
(NeCH2eCH]CH2), 126.6 (C-4a), 126.5 (C-5), 123.5 (C-10), 123.3
(C-6), 117.5 (NeCH2eCH]CH2), 115.9 (C8), 109.3 (C-3), 50.0
(NeCH2eCH]CH2), 33.0 (C-30), 31.8 (C-110), 29.6 (C-100), 29.5 (C-90),
29.5 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6
(C-120), 14.0 (C-130). ESI-MS m/z (%): [M þ 1]þ 366 (100), 324
[M þ 2eC3H5]þ, 306, 224, 210, 198, 184, 146, 107.
4.2.3.26. 1-Pentyl-2-[(1E)-tridecenyl]-4-(1H)-quinolone (20f). Prepared
from (E)-3-pentadecen-2-one (8) (1.5 g, 6.7mmol) in THF (25mL), LDA
(3.4 mL, 6.7 mmol) and N-pentyl isatoic acid anhydride (15) (1.17 g,
5.0 mmol) in THF (20 mL). 20f was formed as a yellow semisolid
(0.98 g, 50%). IR (KBr, nmax cm1): 3424, 2925, 2854, 1624, 1598, 1486,
1422, 759. 1H NMR: d 8.43 (dd, J¼ 8.0,1.6 Hz,1H, H-5), 7.62 (td, J¼ 8.0,
1.6 Hz,1H, H-7), 7.44 (d, J¼ 8.4 Hz,1H, H-8), 7.32 (t, J¼ 7.6 Hz,1H, H-6),
6.41 (d, J¼ 15.2 Hz,1H, H-10), 6.38 (s,1H, H-3), 6.34 (dt, J¼ 15.2, 6.8 Hz,
1H, H-20), 4.11 (t, J ¼ 8.4 Hz, 2H, NeCH2e(CH2)3eCH3), 2.26 (q,
J ¼ 6.8 Hz, 2H, H-30), 1.80 (m, 2H, NeCH2eCH2e(CH2)2eCH3), 1.49
(quint, J¼ 7.2Hz, 2H, H-40),1.41e1.37 (m, 4H,Ne(CH2)2eCH2eCH2eCH3),
1.34e1.22 (m,16H,H-50e120), 0.94 (t, J¼ 6.8Hz, 3H,Ne(CH2)4eCH3), 0.86
(t, J ¼ 6.8 Hz, 3H, H-130). 13C NMR: d 177.6 (C-4), 151.9 (C-2), 141.9 (C-20),
140.4 (C-8a),132.0 (C-7),126.8 (C-4a),126.8 (C-5),123.5 (C-10), 123.1 (C-6),
115.4 (C-8), 109.7 (C-3), 47.5 (NeCH2e(CH2)3eCH3), 33.1 (C-30), 31.9 (C-
110), 29.6 (C-100), 29.6 (C-90), 29.5 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1
(C-50), 28.7 (NeCH2eCH2e(CH2)2eCH3), 28.6 (C-40), 28.3
(Ne(CH2)2eCH2eCH2eCH3), 22.6 (C-120), 22.3 (Ne(CH2)3eCH2eCH3),
14.0 (C-130),13.9 (Ne(CH2)4eCH3). ESI-MSm/z (%): [Mþ 1]þ 396 (100),
324 [M þ 2eC5H11]þ, 310, 282, 256, 240, 198, 184, 159.
4.2.3.27. 1-Propyl-2-[(1E)-tetradecenyl]-4-(1H)-quinolone
(21b). Prepared from (E)-3-hexadecen-2-one (9) (1.5 g, 6.3 mmol)
in THF (25 mL), LDA (3.2 mL, 6.3 mmol) and N-propyl isatoic acid
anhydride (11) (0.96 g, 4.7 mmol) in THF (20 mL). 21b was formed
as light yellow oil (0.87 g, 49%). IR (KBr, nmax cm1): 3422, 2924,
2853, 1625, 1598, 1485, 1422, 759. 1H NMR: d 8.44 (d, J ¼ 8.0 Hz, 1H,
H-5), 7.64 (t, J¼ 7.6 Hz, 1H, H-7), 7.45 (d, J¼ 8.0 Hz, 1H, H-8), 7.34 (t,
J ¼ 7.6 Hz, 1H, H-6), 6.42 (s, 1H, H-3), 6.26 (d, J ¼ 14.8 Hz, 1H, H-10),
6.36 (dt, J ¼ 14.8, 6.4 Hz, 1H, H-20), 4.10 (t, J ¼ 8.0 Hz, 2H,
NeCH2eCH2eCH3), 2.27 (q, J ¼ 6.8 Hz, 2H, H-30), 1.84 (m, 2H,
NeCH2eCH2eCH3), 1.50 (m, 2H, H-40), 1.38e1.22 (m, 18H, H-
50e130),1.04 (t, J¼ 7.2 Hz, 3H,Ne(CH2)2eCH3), 0.87 (t, J¼ 7.2 Hz, 3H,
H-140). 13C NMR: d 177.5 (C-4), 152.0 (C-2), 142.1 (C-20), 140.4 (C-8a),
132.1 (C-7), 126.8 (C-4a), 126.8 (C-5), 123.5 (C-10), 123.2 (C-6), 115.5
A.A. Wube et al. / European Journal of Medicinal Chemistry 46 (2011) 2091e21012100(C-8), 109.6 (C-3), 49.0 (NeCH2eCH2eCH3), 33.1 (C-30), 31.9 (C-120),
29-6 (C-110), 29.6 (C-100), 29.6 (C-90), 29.6 (C-80), 29.4 (C-70), 29.3
(C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-130), 22.0 (NeCH2eCH2eCH3),
14.1 (C-140), 11.0 (Ne(CH2)2eCH3). ESI-MS m/z (%): [M þ 1]þ 382
(100), 340, 326, 312, 298, 254, 172, 107.
4.2.3.28. 1-(2-Propenyl)-2-[(1E)-tetradecenyl]-4-(1H)-quinolone
(21c). Prepared from (E)-3-hexadecen-2-one (9) (1.5 g, 6.3 mmol)
inTHF (25mL), LDA (3.2mL, 6.3mmol) andN-2-propenyl isatoic acid
anhydride (12) (0.95 g, 4.7mmol) in THF (20mL). 21cwas formed as
a light yellow semisolid (0.76 g, 43%). IR (KBr, nmax cm1): 3445,
2919, 2849, 1622, 1599, 1488, 1425, 755. 1H NMR: d 8.39 (dd, J¼ 8.4,
1.6Hz,1H,H-5), 7.56 (td, J¼8.4,1.6Hz,1H,H-7), 7.34 (d, J¼7.6Hz,1H,
H-8), 7.29 (t, J ¼ 7.6 Hz, 1H, H-6), 6.39 (s, 1H, H-3), 6.35 (dt, J ¼ 15.6,
6.8 Hz, 1H, H-20), 6.30 (d, J ¼ 15.6 Hz, 1H, H-10), 6.00 (m, 1H,
NeCH2eCH]CH2), 5.27 (d, J ¼ 10.4 Hz, 1H, NeCH2eCH]CHHb),
4.98 (d, J¼ 17.2 Hz, 1H, NeCH2eCH]CHaH), 4.73 (dt, J¼ 4.0, 1.6 Hz,
2H, NeCH2eCH]CH2), 2.22 (q, J ¼ 6.8 Hz, 2H, H-30), 1.46 (m, 2H,
H-40),1.33e1.20 (m,18H, H-50e130), 0.85 (t, J¼ 6.8 Hz, 3H, H-140). 13C
NMR: d 177.8 (C-4),152.1 (C-2),142.1 (C-20),140.8 (C-8a),132.0 (C-7),
131.1 (NeCH2eCH]CH2), 126.7 (C-4a), 126.5 (C-5), 123.2 (C-10),
123.2 (C-6), 117.4 (NeCH2eCH]CH2), 115.9 (C-8), 109.3 (C-3), 49.9
(NeCH2eCH]CH2), 33.0 (C-30), 31.8 (C-120), 29.6 (C-110), 29.5
(C-100), 29.5 (C-90), 29.5 (C-80), 29.3 (C-70), 29.2 (C-60), 29.1 (C-50),
28.5 (C-40), 22.6 (C-130), 14.0 (C-140). ESI-MS m/z (%): [M þ 1]þ 380
(100), 338 [M þ 2eC3H5]þ, 310, 224, 210, 198, 184, 172, 146.
4.2.3.29. 1-(2-Propynyl)-2-[(1E)-tetradecenyl]-4-(1H)-quinolone
(21d). Prepared from (E)-3-hexadecen-2-one (9) (1.5 g,
6.3 mmol) in THF (25 mL), LDA (3.2 mL, 6.3 mmol) and N-2-
propynyl isatoic acid anhydride (13) (0.95 g, 4.7 mmol) in THF
(20 mL). 21d was formed as a light yellow solid (0.79 g, 45%). IR
(KBr, nmax cm1): 3446, 3179, 2921, 2848, 2113, 1622, 1597,
1487, 1420, 763. 1H NMR: d 8.40 (d, J ¼ 8.0 Hz, 1H, H-5), 7.69 (t,
J ¼ 8.0 Hz, 1H, H-7), 7.59 (d, J ¼ 8.4 Hz, 1H, H-8), 7.37
(t, J ¼ 7.6 Hz, 1H, H-6), 6.50 (d, J ¼ 16.0 Hz, 1H, H-10), 6.43 (dt,
J ¼ 16.0, 6.4 Hz, 1H, H-20), 6.41 (s, 1H, H-3), 4.84 (s, 2H,
NeCH2eChCH), 2.48 (s, 1H, NeCH2eChCH), 2.30 (q, J ¼ 6.8 Hz,
2H, H-30), 1.51 (m, 2H, H-40), 1.38e1.22 (m, 18H, H-50e130), 0.87
(t, J ¼ 6.8 Hz, 3H, H-140). 13C NMR: d 177.9 (C-4), 151.7 (C-2),
143.0 (C-20), 140.5 (C-8a), 132.4 (C-7), 126.7 (C-4a), 126.6 (C-5),
123.6 (C-10), 122.9 (C-6), 115.5 (C-8), 109.6 (C-3), 76.8
(NeCH2eChCH), 74.9 (NeCH2eChCH), 38.1 (NeCH2eChCH),
33.1 (C-30), 31.9 (C-120), 29.6 (C-110), 29.6, (C-100), 29.6 (C-90),
29.6 (C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6
(C-130), 14.1 (C-140). ESI-MS m/z (%): [M þ 1]þ 378 (100), 338,
310, 210, 198, 184, 172, 146.
4.2.3.30. 1-Butyl-2-[(1E)-tetradecenyl]-4-(1H)-quinolone (21e). Prepared
from (E)-3-hexadecen-2-one (9) (1.5 g, 6.3 mmol) in THF (25 mL),
LDA (3.2 mL, 6.3 mmol) and N-butyl isatoic acid anhydride (14)
(1.03 g, 4.7 mmol) in THF (20 mL). 21e was formed as yellow oil
(0.81 g, 44%). IR (KBr, nmaxcm1): 3422, 2925, 2853,1625,1598,1485,
1423, 759.1HNMR: d8.43 (dd, J¼8.0,1.6Hz,1H,H-5), 7.63 (td, J¼8.0,
1.6 Hz,1H, H-7), 7.46 (d, J¼ 8.4 Hz,1H, H-8), 7.33 (t, J¼ 7.6 Hz,1H, H-
6), 6.43 (d, J ¼ 15.6 Hz, 1H, H-10), 6.42 (s, 1H, H-3), 6.36 (dt, J ¼ 15.6,
6.0 Hz, 1H, H-20), 4.12 (t, J ¼ 7.6 Hz, 2H, NeCH2e(CH2)2eCH3), 2.27
(q, J ¼ 6.8 Hz, 2H, H-30), 1.79 (quint, J ¼ 7.2 Hz, 2H,
NeCH2eCH2eCH2eCH3), 1.48 (quint, J ¼ 7.2 Hz, 2H, H-40), 1.42 (m,
2H, Ne(CH2)2eCH2eCH3), 1.32e1.22 (m, 18H, H-50e130), 1.01 (t,
J ¼ 7.6 Hz, 3H, Ne(CH2)3eCH3), 0.86 (t, J ¼ 6.8 Hz, 3H, H-140). 13C
NMR: d 177.5 (C-4),152.0 (C-2),142.0 (C-20),140.4 (C-8a),132.0 (C-7),
126.8 (C-4a), 126.8 (C-5), 123.5 (C-10), 123.2 (C-6), 115.4 (C-8), 109.6
(C-3), 47.3 (N-CH2e(CH2)2eCH3), 33.1 (C-30), 31.8 (C-120), 30.6
(NeCH2eCH2eCH2eCH3), 29.6 (C-110), 29.6 (C-100), 29.6 (C-90), 29.5(C-80), 29.4 (C-70), 29.3 (C-60), 29.1 (C-50), 28.6 (C-40), 22.6 (C-130),
19.9 (Ne(CH2)2eCH2eCH3), 14.0 (C-140), 13.6 (Ne(CH2)3eCH3). ESI-
MSm/z (%): [M þ 1]þ 396 (100), 338 [M þ 2eC4H9]þ, 296, 282, 242,
226, 198, 172, 159, 130, 107.4.3. In vitro antimycobacterial assay
The synthetic compounds were evaluated for mycobacterial
growth inhibitory effect as previously described method [19] on
96-wells using a microdilution assay. The mycobacterial strains,
which were cultivated on Columbia blood agar supplemented
with 7% deﬁbrinated horse blood and prepared in 0.9% NaCl
solution to get inoculum’s density of 5  105 cells/mL, were
dispensed into each well, except the blank. 125 mL of each test
material solution and the standard antibiotic, prepared by dis-
solving in DMSO and further dilution in MHB, were added to
well 1 of the lane in duplicate followed by serial double dilu-
tions to well 10 of the lane, so that the ﬁnal concentration
ranged from 128 mg/L at well 1 to 0.25 mg/L at well 10. The last
two wells in the lane were used as a sterile and growth control
respectively. Isoniazid was used as a positive control and tests
were repeated three times. Growth inhibition was determined
after 3 days of incubation at 37 C and methanol solution of
tetrazolium redox dye (MTT) was employed as mycobacterial
growth indicator producing a dark violet colouration when
there is growth.4.4. Cytotoxicity assay
Cytotoxicity was assessed using human diploid embryonic lung
cell line MRC-5 as previously described method [20] with some
modiﬁcations. Growth inhibitory effect of respective samples on
cells was measured by XTT proliferation assay.
The toxicity of compounds was determined by means of the
XTT Cell Proliferation Kit II (Roche Diagnostics, Mannheim,
Germany). Fresh stock solutions of each compound were prepared
in Ethanol and afterwards diluted with buffer or water, respec-
tively. Cells were seeded at a concentration of 5  104 cells/well
and cultivated for 24 h in 96-well culture plates. Marginal wells
were ﬁlled with 100 mL of pure medium (MEM) in order to
minimize effects of evaporation. Besides, wells ﬁlled with medium
were required to determine the background absorbance caused by
non-metabolized XTT. A row of wells containing cells treated with
ethanol (0.1%) served as solvent control. The other rows of wells
containing cells were supplemented with different concentrations
of the respective compound. Each concentration was tested in
triplicate in at least two independent plates containing different
batches of cells (n ¼ 6).
After incubation for 72 hwith respective compounds at 37 C, 5%
CO2 in humidiﬁed atmosphere, XTT reagent was freshly prepared
and added to each well as speciﬁed by the manufacturer: XTT-
labelling reagent and electron-coupling reagent were mixed in
a ratio of 50:1 and 50 mL of this mixture were added to each well of
the 96-well plate. The plates were incubated for additional 4 h at
37 C, 5% CO2 in humidiﬁed atmosphere and read out afterwards.
Quantiﬁcation of cell viability was performed with a microplate
reader at 490 nm with a reference wavelength of 655 nm. Absor-
bance values at both wavelengths were subtracted. The cytotoxic
effect of the treatment was determined as percentage of viability
compared to cells treated with solvent solely.
Cell viabilityð%Þ ¼ AbsorbanceðsampleÞ490nm 650nm
AbsorbanceðcontrolÞ490nm 650nm
 100
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